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ABSTRACT 
 
The incidence of type 2 diabetes (T2D) is persistently increasing globally. T2D is associated 
with pancreatic β cell dysfunction and insulin resistance in peripheral tissues such as the liver 
and skeletal muscle. Skeletal muscle is the major site for insulin stimulated glucose uptake. 
Maintenance on a gestational high fat diet may programme insulin resistance. Programming 
is induced by the exposure of organisms to either a stimulus or insult during foetal and/or 
early neonatal life and alters offspring physiology and metabolism. The aim of the present 
study was therefore to investigate the effects of maternal diets, varying in fat content, on 
neonatal hepatic and skeletal muscle gene (mRNA) and protein (immunoreactivity) 
expression of proximal insulin signalling factors: insulin receptor alpha (IRα), insulin 
receptor substrate 2 (IRS2) and phosphoinositide 3-kinase-p110 alpha (PI3K-p110α), and to 
assess the therapeutic potential of Aspalathus linearis extract after high fat programming.  
Pregnant rats were randomised into groups maintained on diets with varying fat proportions: 
10% (control), 20% (20F), 30% (30F) and 40% (40F) fat as energy throughout gestation. 
Neonatal liver and skeletal muscle were collected to determine the proximal insulin signalling 
expression profiles of the target factors: IRα, IRS2 and PI3K-p110α. Quantitative polymerase 
chain reaction (qPCR) was applied to determine mRNA expression of these target insulin 
signalling factors. Immunostaining of the target proteins in the liver and skeletal muscle was 
performed followed by relative quantification with image analysis software. Further, 
Aspalathus linearis (Al) extract was orally administered to mothers during gestation in the 
10% (Control-Al) and 40% (HFD-Al) diets at a dose of 150 mg/kg. Body weight, food intake 
and blood glucose concentrations were monitored throughout gestation in mothers.  
 
Maternal diets, varying in the percentage of fat content, showed no significant effect on 
neonatal hepatic IR and IRS2 mRNA expression. However, hepatic PI3K mRNA expression 
was elevated in 30F neonates compared to 20F neonates. Skeletal muscle IR and PI3K 
mRNA expression were reduced in the 30F and 40F neonates compared to 20F neonates. 
There was reduced hepatic IRα immunoreactivity in 40F neonates compared to control and 
20F neonates. Further, skeletal muscle IRα immunoreactivity was significantly reduced in 
30F and 40F neonates compared to control neonates. Therefore foetal high fat programming 
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reduced IRα in both the liver and skeletal muscle which may impair proximal insulin 
signalling in these glucose recipient organs. Aspalathus linearis had no effect on maternal 
serum insulin and glucagon concentrations. In addition, maternal caloric intake, body weight 
and organ weights (liver, brain and pancreas) were not altered amongst the groups. Further, 
HFD-Al neonates were heavier than control neonates. In conclusion, Aspalathus linearis, at a 
dose of 150 mg/kg, had neither harmful nor ameliorative effects in pregnant mothers fed high 
fat diet during gestation. In addition, Aspalathus linearis treatment had no ameliorative 
effects on neonates from mothers fed high fat diet throughout gestation.  
.  
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CHAPTER 1 
LITERATURE REVIEW 
 
1.1 Diabetes 
Diabetes is a chronic metabolic disorder characterised by an abnormal elevation in blood 
glucose concentrations (hyperglycaemia). Pancreatic β cells produce insulin, a hormone that 
stimulates glucose uptake from the blood stream into peripheral tissues. Diabetes may present 
due to β cell failure to synthesise and/or secrete insulin, or insulin resistance in peripheral 
(glucose recipient) tissues such as skeletal muscle, liver and adipose tissue (Lin and Sun, 
2010). Type 1 (T1D), type 2 (T2D) and gestational diabetes mellitus (GDM) are the major 
forms of diabetes. T1D mostly occurs in children and adolescents and is an autoimmune 
disorder characterised by few or no pancreatic β cells that results in reduced insulin 
production (Ku et al., 2012). T2D is mainly due to β cell dysfunction and insulin resistance 
(Ku et al., 2012) although this association remains complex. GDM first occurs during 
pregnancy and may disappear upon delivery or progress to T2D. The symptoms of diabetes 
include thirst, excessive urination, unexplained weight loss, blue-red vision, lethargy and 
changes in energy production (Lin and Sun, 2010; Spellman, 2010). 
1.1.2 Type 2 diabetes mellitus (T2D) 
1.1.2.1 Overview on the prevalence of T2D 
T2D has increased in all age groups globally. The number of people with diabetes was 
projected to increase from 171 million in 2000 to 366 million by 2030 (Wild et al., 2004). 
This projection signals that the number of individuals with diabetes will be double by 2030. 
T2D is linked with an increase in obesity, one of the core factors in metabolic syndrome 
(MetS) and insulin resistance. An increase in T2D and obesity results due to nutritional 
transition to a westernised diet and sedentary lifestyle particularly in developing countries 
(Gupta et al., 2012). Nutritional transition can be driven by urbanisation, globalisation and 
social changes (Amuna and Zotor, 2008). People tend to change their traditional diets (plant 
based food) due to urbanisation to adopt more westernised diets. Traditional diets contain 
more fibre and low fat unlike westernised diets that contain low fibre, high fat and 
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carbohydrate content that may lead to obesity. Obesity is associated with development of 
T2D and cardiovascular diseases.  
1.1.2.2 Overview of the pathophysiology of T2D 
Physiologically, insulin is constantly synthesised by pancreatic β cells and stored in vacuoles 
regardless of circulating glucose concentrations (Lin and Sun, 2010; Spellman, 2010). Insulin 
release from the vacuoles is triggered by elevated circulating glucose concentrations. In 
addition to glucose uptake, insulin converts glucose to glycogen for internal storage in 
skeletal muscle and liver (Seino, 2012; Spellman, 2010). In response to hypoglycaemia, 
glucagon is released from the pancreatic α cells. On the other hand, the insulin is released 
from pancreatic β cells to maintain glucose homeostasis (Seino, 2012).   
Glucose homeostasis is impaired in T2D. Apart from β cell failure, insulin resistance is the 
major pathophysiological event in T2D (Lin and Sun, 2010). Pancreatic β cell failure to 
synthesise and secrete insulin further exacerbates hyperglycaemia (Lin and Sun, 2010; 
Spellman, 2010). In addition, factors such glucotoxicity, lipotoxicity, oxidative stress, 
endoplasmic reticulum (ER) stress and adipokines can reduce pancreatic β cell mass and 
function (Weir and Bonner-Weir, 2013). These factors can directly or indirectly lead to 
pancreatic β cell failure and demise.  
1.1.3 Gestational diabetes mellitus (GDM) 
GDM is glucose intolerance first detected during pregnancy (Gobl et al., 2013). Pregnant 
women can be screened for clinical risk factors such as pre-diabetes, impaired glucose 
tolerance, maternity age (women >35 are more susceptible to GDM), overweight, obesity and 
family history of T2D (Gobl et al., 2013). GDM results from an inadequate supply of insulin 
to tissues for normal blood glucose regulation and it accounts for about 3-10% of pregnancies 
depending on the population (Buchanan and Xiang, 2005).  
1.2 Metabolic Syndrome (MetS) 
MetS is important for the identification and diagnosis of individuals at high risk for T2D and 
cardiovascular disease (Alberti et al., 2005). MetS refers to a cluster of metabolic risk factors, 
including central obesity, insulin resistance, dyslipidaemia, glucose intolerance and 
hypertension (Eckel et al., 2010; Shen et al., 2003; Alberti et al.,2005) and is also known as 
syndrome X or the insulin resistance syndrome (Eckel et al. 2005).  
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Table 1: Metabolic syndrome as defined by the World Health Organization (WHO) 
Core factors of MetS Values  
Diabetes or impaired fasting glycaemia, 
impaired glucose tolerance or insulin 
resistance  
Hyperinsulinaemic, euglycaemic clamp-glucose 
uptake in lowest 25% 
Obesity BMI >30 or waist to hip ratio >0.9 (male) or 
>0.85 (females)  
Dyslipidaemia  Triglycerides ≥1.7 mmol/L or HDL-cholesterol 
<0.9 (male) or 1.0 (female) mmol/L  
Hypertension  Blood pressure ≥140/90 mmHg  
Microalbuminuria Albumin excretion >20µg/min 
Fasting plasma glucose  Glucose concentration ≥6.1 mmol/L 
Adapted from Eckel et al 2005 
1.2.1 Factors contributing to MetS (Table 1) 
1.2.1.1 Insulin resistance 
The overabundance of circulating fatty acids is a major contributor to insulin resistance 
(Eckel et al., 2005). Plasma albumin-bound free fatty acids (FFA) are derived from adipose 
tissue triglyceride stores and released through the action of cyclic AMP-dependent enzyme 
hormone sensitive lipase (Eckel et al., 2005). Lipolysis of triglycerides in tissues by the 
action of lipoprotein lipase increases the concentrations of circulating of FFA (Wang and 
Eckel, 2009; Bruckert and Dejager, 1994). Insulin is important for both anti-lipolysis and the 
stimulation of lipoprotein. Plasma FFA can inhibit insulin stimulated glucose transport and 
phosphorylation in peripheral tissues and also inhibit glycogen synthase activity 
(Straczkowski and Kowalska, 2008). Elevated FFA inhibits insulin action on endogenous 
glucose production in the liver and enhances gluconeogenesis. The generation of excess acyl 
CoAs or acyl-CoA derivatives such as sphingolipid ceramide can reduce Akt1 activation 
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(Straczkowski and Kowalska, 2008; de la Monte et al., 2010). Glycerolipids such as 
diacylglycerol (DAG) derived from long-chain acyl-coenzymes A (LC-ACoA) inhibit insulin 
receptor substrate 1 (IRS1) phosphorylation via activation of PKC-θ and PKC-ε, and 
phosphatidylinositol 3-kinase (PI3K) activity (Straczkowski and Kowalska, 2008; Erion and 
Shulman, 2010). 
 
Figure 1.1: Molecular mechanism of insulin resistance in skeletal muscle and liver 
Taken from Erion and Shulman, 2010 
1.2.1.2 Central obesity 
Central or abdominal obesity is defined by an increase in waist to thigh ratio, waist 
circumference and sagittal abdominal diameter (Iribarrene et al., 2006). Obesity is linked to 
an increased risk of cardiovascular disease. Central obesity is associated with a higher risk of 
heart disease, hypertension, insulin resistance and T2D (Buettner et al., 2007).  
Despite the importance of obesity in MetS, people of normal weight can also develop MetS 
(Ruderman et al., 1998; Hayes et al., 2010). Intra-abdominal adipose tissue-derived FFA can 
enter the liver through splanchnic circulation and have direct effects on hepatic metabolism 
(including glucose production and lipid synthesis) (Aubert et al., 2003). 
1.2.1.3 Dyslipidaemia 
Dyslipidaemia occurs with an increase in FFA flux to the liver and increased production of 
apo B-containing triglyceride-rich very low-density lipoproteins (Lewis et al., 1995; Darioli 
et al., 2002). Insulin resistance and increased flux of FFA to the liver increases hepatic 
triglyceride synthesis; however, under physiological conditions, insulin inhibits rather than 
increases the secretion of very low-density lipoproteins into the systemic circulation (Soska, 
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2003). This response is partially due to insulin’s effect on the degradation of apo B (Eckel at 
al., 2005). MetS is also characterised by a reduction of high density lipoprotein (HDL) 
cholesterol. In the presence of hypertriglyceridaemia, a decrease in the cholesterol content of 
HDL results from decreases in the cholesteryl ester content of the lipoprotein core with 
variable increases in triglyceride rendering the particle small and dense (He et al., 2008). This 
change in lipoprotein composition also results in increased clearance of HDL from circulation 
(Tian et al., 2010; He et al., 2008).  
1.2.1.4 Glucose intolerance  
Glucose intolerance includes deficiencies in the ability of the hormone to suppress glucose 
production by the liver and kidney and to mediate glucose uptake and metabolism in insulin 
sensitive tissues such as the muscle, liver and adipose tissue (Eckel et al., 2005).  
1.2.1.5 Hypertension  
Insulin is a vasodilator when administered intravenously to people of normal weight (Eckel et 
al. 2005, Steinberg et al., 1994), with secondary effects on sodium reabsorption in the kidney 
(Eckel et al. 2005). In insulin resistant patients, the vasodilatory effect of insulin is usually 
lost (Tooke and Hannemann, 2000) whereas the renal effect on sodium reabsorption is 
preserved (Kuroda et al., 1999). FFA can mediate relative vasoconstriction (Tripathy et al., 
2003). Insulin also increases the activity of the sympathetic nervous system, an effect that 
may be preserved in insulin resistance (Eckel et al., 2005).  
1.3 Developmental programming 
Growth and development in utero is a complex dynamic process requiring interacting 
components from the mother and foetus to sustain optimal foetal growth and survival 
throughout pregnancy (Warner and Ozanne, 2010). Programming refers to effects of an 
altered metabolic environment during a critical or sensitive period of development inducing 
immediate, transient or durable effects in offspring (O'Brien et al., 2008). The physiology and 
metabolism of the foetus and neonate can be altered by an insult or stimulus during critical 
developmental periods. Maternal nutrition plays an important role in the health of the 
offspring, with maternal high fat feeding inducing deleterious effects on pancreatic islet 
development and altering the expression, both at gene and protein level, of key genes 
involved in pancreatic β cell maintenance (Cerf et al., 2005; Cerf et al., 2006). An increase in 
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the prevalence of metabolic diseases in adult life is associated with an imbalance in energy 
intake and expenditure (Grant et al., 2011). Emerging evidence suggests that the response to 
metabolic challenges during postnatal life is modified by environment influences during 
foetal development (Grant et al., 2011). The exposure to an environmental insult at a critical 
stage has permanent effects on the structure of organs, tissue and systems in offspring (Grant 
et al., 2011). 
 
Figure 1.2: Developmental programming  
Adapted from Alfaradhi and Ozanne, 2011 
1.3.1 Maternal high fat diet 
Strong evidence suggests that maternal nutrition during pregnancy can programme nutritional 
imbalances that may lead to obesity (Grant et al., 2011). Among other factors, maternal 
obesity and GDM have been implicated in the development of metabolic disorders, impaired 
glucose tolerance and risk of developing obesity and diabetes in adulthood (Boney et al., 
2005; Grant et al., 2011). An increase in the consumption of low nutrient dense foods 
(carbohydrates and saturated fat) was identified as major contributors of energy in a cohort of 
pregnant woman (Grant et al., 2011; Siega-Riz et al., 2002). The exposure to diets rich in 
animal fat during gestation and lactation may contribute to offspring obesity and the 
development of MetS (Ashino et al., 2011). Offspring from mothers fed a high fat diet 
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presented clinical features of MetS, lipid accumulation and activation of c-Jun N-terminus 
kinases consistent with the development of non-alcoholic fatty liver disease (Ashino et al., 
2011). High fat diets directly insult β cells, which respond by increasing both replication and 
neogenesis resulting in increased β cell mass and hyperinsulinaemia (Gniuli et al., 2008). 
This dietary insult can be permanent on the β cell function of the foetus and also worsen in 
early neonatal life (Gniuli et al., 2008). Another study demonstrated that 12 week old 
offspring from mothers fed lard rich diets were insulin resistant compared to offspring from 
mothers fed polysaturated fat rich fish oil (Taylor et al., 2005). 
1.3.2 Maternal obesity 
Maternal high fat consumption often leads to maternal obesity. Maternal obesity has an 
independent effect on high fat feeding on programming adiposity, hyperphagia and insulin 
resistance (Alfaradhi and Ozone, 2011). Offspring exposed to maternal obesity during 
gestation and lactation while maintained on high fat diet displayed an increase in weight gain 
and fat mass (Shankar et al., 2008). Maternal obese mothers displayed hyperleptinemia in 
both serum and milk during lactation compared to non-obese mothers (White et al., 2009). 
Offspring from maternal obese mothers were insulin insensitive compared to offspring from 
non-obese mothers suggesting that the exposure of neonates to maternal obesity induces an 
increase in body weight similar to the effect of offspring maintained on high fat diets in adult 
life (White et al., 2009). 
1.3.3 Impaired glucose tolerance and GDM 
Obesity is a risk factor for the development of T2D and the development of glucose 
intolerance during gestation leading to GDM (Buchanan and Xiang, 2005). Reduced insulin 
sensitivity and inadequate insulin response are metabolic defects related to development of 
GDM (Buchanan and Xiang, 2005). Maternal hyperglycaemia leads to maternal insulin 
resistance that may lead to offspring obesity (Chandler-Laney and Bush 2011). Offspring 
from obese mothers with GDM developed intrahepatic fat which may lead to non-alcoholic 
fatty liver disease and insulin resistance (Brumbaugh et al., 2013). Insulin is known to induce 
adiposity; foetal hyperinsulinaemia is associated with adiposity in young and adult life 
(Chandler-Laney and Bush 2011). Therefore maternal glucose is hypothesised to increase 
foetal insulin concentrations that may alter foetal programming (Chandler-Laney and Bush 
2011).  
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1.3.4 Hyperlipidaemia 
Lipids also play a role in reducing insulin sensitivity as an increase in FFA concentrations 
impair the ability of insulin to suppress lipolysis in late gestation (Catalano, 2010). Increased 
FFA also provides energy in late gestation to meet maternal energy requirements. The 
increased FFA may also play a role in excessive foetal growth. Although foetal insulin 
production is stimulated by increased glucose production as observed in obese and gestational 
diabetic women, the nutrient substrates for foetal growth, particularly in adiposity, are less 
described (Catalano, 2010). Total cholesterol, HDL cholesterol and triglyceride 
concentrations increase in normal pregnancy compared to non-pregnant women (Chandler-
Laney and Bush 2011). In comparison to lean pregnant women, obese pregnant women have 
higher triglyceride and lower HDL cholesterol concentrations (Chandler-Laney and Bush 
2011). Elevated cholesterol and triglyceride concentrations either prior to or during 
pregnancy are associated with increased risk of complications during pregnancy such as 
preeclampsia, glucose intolerance and GDM (Chandler-Laney and Bush 2011). In a study in 
women with well controlled GDM, maternal FFA and triglyceride concentrations were 
positively associated with foetal abdominal circumference during the third trimester 
(Schaefer-Graf et al., 2008). Those parameters measured close to delivery were positively 
associated with concentrations measured in cord blood, increased the risk of delivering large 
for gestational age (LGA) infants (Schaefer-Graf et al., 2008). Elevated maternal triglyceride 
concentrations in these women were also associated with increased neonatal fat mass 
(Schaefer-Graf et al., 2008). 
1.3.6 Leptin 
Maternal leptin is produced from adipose stores and the placenta (Henson and Castracane, 
2006). During pregnancy and lactation, leptin modulates energy expenditure and metabolism 
(Stocker et al., 2005). During early life, both insulin and leptin function as trophic factors and 
have been shown to impact neuronal development during early life (Bouret and Simerly, 
2004). The lack of leptin, as observed in ob/ob mice, has been shown to underlie the 
development of obesity in these mice (Bouret et al., 2004; Srinivasan et al., 2008). Abnormal 
insulin concentrations in the foetal or early postnatal periods induce alterations in the 
hypothalamic appetite regulating mechanisms resulting in adult onset obesity (Srinivasan et 
al., 2008). The roles of leptin and insulin in regulating feeding behaviour in adults are well 
established. The functional leptin receptor, ObRb, is largely expressed in brain regions 
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known to control energy balance. Leptin administration in postnatal mice has been shown to 
act on neuropeptide Y (NPY) and pro-opiomelanocortin (POMC) neurons (Caron et al., 
2010).  
1.4 Insulin signalling  
1.4.1 Insulin secretion  
Circulating glucose is derived from three sources: (1) intestinal absorption during the fed 
state, (2) conversion of glycogen to glucose (glycogenolysis), and (3) generation of glucose 
(gluconeogenesis) from non-carbohydrate substrate such as lactate, glycerol and glucogenic 
amino acids in the liver (Aronoff et al., 2004). Under physiological conditions, plasma 
glucose concentrations are determined by the rate at which glucose enters the circulation and 
balanced by the rate of glucose removal (glucose uptake) from blood (Aronoff et al., 2004).  
Pancreatic β cells are derived from neuroendocrine cells and equipped to sense nutrients, 
primarily glucose (Aronoff et al., 2004). β cells function as glucose sensors with the 
important task of adjusting insulin release to control blood glucose concentrations (Maechler 
et al., 2005; Henquin, 2000). Insulin and glucagon are effective regulators of glucose 
metabolism (Aronoff et al., 2004). The hormone, insulin, is synthesised and secreted by 
pancreatic β cells. Insulin is a small protein composed of two polypeptide chains containing 
51 amino acids (Aronoff et al., 2004). The actions of insulin affect glucose metabolism, 
storage of ingested nutrients, glucose uptake by the cells and the use of glucose as the 
primary source of energy (Aronoff et al., 2004). Insulin also promotes protein and fat 
synthesis (Aronoff et al., 2004). Like other hormones, insulin’s actions are mediated through 
binding to its receptors present on many cells of the body including myocytes, hepatocytes 
and adipocytes (Aronoff et al, 2004).  
Insulin secretion occurs when glucose is metabolised in the β cell and the ATP/ADP ratio 
increases (Ashcroft et al., 1994; Winzell et al., 2006). This leads to closure of ATP-sensitive 
K
+
-channels, depolarisation of the cell membrane and opening of voltage-gated Ca
2+
-
channels resulting in a rise in intracellular Ca
2+
 which, in turn, results in insulin excocytosis 
(Ashcroft et al., 1994; Winzell et al., 2006). Insulin’s primary action is to stimulate glucose 
clearance (Aronoff et al., 2004). The insulin signalling pathway is triggered when insulin 
stimulates insulin sensitive peripheral tissues such as the skeletal muscle and liver to increase 
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their glucose uptake (Aronoff et al., 2004). Insulin then acts on the liver to promote 
glycogenesis (Aronoff et al., 2004). Finally, insulin simultaneously inhibits glucagon 
secretion from pancreatic α cells and signals the liver to stop glycogenolysis and 
gluconeogenesis (Girard, 2006; Choukem and Gautier, 2008). 
1.4.2 Overview of insulin signalling and insulin receptor (IR) phosphorylation  
IR is a trans-membrane receptor (Ward and Lawrence, 2009; Patti and Kahn, 1998) that 
belongs to the sub-family of receptor tyrosine kinases that includes insulin like-growth factor 
(IGF) and insulin-related receptor (IRR) (Patti and Kahn, 1998; Saltiel and Kahn, 2001). IR is 
composed of two extracellular α subunits and two trans-membrane β subunits linked by 
disulphide bonds (Ward and Lawrence, 2009). Binding of insulin to the α-subunit causes a 
conformational change resulting in autophosphorylation of tyrosine residues present on β 
subunits (Van et al., 2001). Adaptor proteins such as members of the insulin receptor 
substrate (IRS) family have phosphotyrosine binding domains that recognise the tyrosine 
residues present in the β subunit (Saltiel and Kahn, 2001; Lizcano and Alessi, 2002). IR 
activation leads to phosphorylation of the key tyrosine residues on IRS proteins, some of 
which are recognised by the Src homology 2 (SH2) domain of the p85 regulatory subunit of 
phosphatidylinositol 3-kinase (PI3K; a lipid kinase) (Saltiel and Kahn, 2001; Ande and 
Mishra, 2009). The catalytic subunit of PI3K, p110, then phosphorylates PtdIns(4,5)P2 on the 
plasma membranes of cells to generate the second messenger PtdIns(3,4,5)P3 (Ande and 
Mishra, 2009). The key downstream effector of PtdIns(3,4,5)P3 in insulin signalling is Akt or 
protein kinase B (PKB) (Lizcano et al., 2002). Akt binds to PtdIns(3,4,5)P3 via a pleckstrin 
homology domain located at its amino terminus (Ande and Mishra, 2009; Scheid and 
Woodgett, 2003). This results in the recruitment of Akt from the cytosol to the plasma 
membrane where PtdIns(3,4,5)P3 is located. The interaction between Akt and PtdIns(3,4,5)P3 
does not directly activate Akt, instead it recruits the other protein kinases that directly 
phosporylate Akt at Thr308 and Ser473 (Scheid and Woodgett, 2003). When Akt is activated, 
it dissociates from the plasma membrane and phosphorylates numerous substrates in the 
cytoplasm and nucleus, which play important roles in regulating insulin dependent processes 
that include glucose uptake, protein synthesis and the regulation of lipid synthesis (Lizcano et 
al 2002). 
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Figure 1.3: Insulin signalling pathway  
Adapted from http://www.cellsignalling.com 
Insulin is the primary hormone that controls both glucose and lipid metabolism. Insulin 
activates insulin receptor (IR) a tyrosine kinase that phosphorylates adaptor proteins that 
include the IRS family proteins. Phosphorylated IRS displays binding sites for PI3K (a lipid 
kinase). PI3K phosphorylates PtdIns(4,5)P2 at the plasma membrane to generate a second 
messenger PtdIns(3,4,5)P3. PtdIns(3,4,5)P3 indirectly activates Akt. Akt induces glycogen 
synthesis by inhibiting GSK-3, protein synthesis via mTOR and GLUT4 translocation to the 
plasma membrane. 
1.4.3 Insulin receptor substrate 1 (IRS1) and insulin receptor substrate 2 (IRS2) 
phosphorylation 
1.4.3.1 IRS1  
IRS1 is one of the key members of IRS family proteins (Gual et al., 2005). IRS1 is tyrosine 
phosphorylated in response to insulin, cytokines and IGF-1 (Patti and Kahn, 1998). In 
response to insulin, IRS1 becomes tyrosine phosphorylated and recruits a number of SH2 
containing signal transducers including PI3K (Gual et al., 2005). Tyrosine phosphorylation of 
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IRS1 initiates insulin signalling. Reductions in tyrosine phosphorylation of IRS1 have been 
reported in 30% of subjects at high risk of obesity and type 2 diabetes (Gual et al., 2005). 
Reduced IRS1 tyrosine phosphorylation and PI3K activation severely impairs insulin 
signalling and glucose transporter 4 (GLUT4) translocation in skeletal myocytes and 
adipocytes (Rains and Jain, 2011). The activation of serine/threonine kinases impairs IRS1 
downstream signalling to PI3K and Akt which reduces GLUT4 expression and translocation 
to the plasma membrane (Rains and Jain, 2011). This subsequently reduces glucose uptake 
and metabolism leading to insulin resistance and eventually T2D (Rains and Jain, 2011). 
Regarding insulin resistance, several studies have suggested that agents that induce insulin 
resistance such as pro-inflammatory cytokines (Kanety et al., 1995), FFA, cellular stresses 
and hyperinsulinaemia can also activate serine/threonine kinases that inhibit phosphorylation 
of IRS1 and inhibit its function (Gual et al., 2005). Pro-inflammatory cytokine gene 
expression of IL6, TNF-α and MCP1 may also lead to insulin resistance and T2D (Rains and 
Jain, 2011). Several studies have reported that TNF-α inhibits tyrosine phosphorylation by 
promoting serine phosphorylation that changes conformation (Rains and Jain, 2011). 
Conformation changes reduce recruitment of PI3K and also stimulate the IRS1 degradation 
pathway (Rains and Jain, 2011). 
1.4.3.2 IRS2 
IRS2 is a cytoplasmic signal molecule that mediates the effects of insulin, IGF-1 and other 
cytokines by acting as a molecular adaptor between receptor tyrosine kinase and downstream 
effectors (Jiang et al., 2000; Valverde et al., 1998). IRS2 was initially identified as an 
alternative substrate in animals with targeted disruption of IRS1 (Sesti et al., 2001). IRS2 
contains 22 potential tyrosine phosphorylation sites with only 13 conserved in IRS1 (Sesti et 
al., 2001). Both IRS1 and IRS2 may regulate unique signalling pathways in different tissues, 
subcellular locations, kinetics activation/deactivation or specific interactions with 
downstream effectors (Sesti et al., 2001). In addition, both IRS1 and IRS2 mediate metabolic 
pathways. Hepatic IRS1 functions immediately after feeding and IRS2 functions mainly 
during fasting (Kubota et al., 2008). IRS2 does not fully compensate for reduced levels of 
IRS1 and only partially compensates for improving insulin action on IRS2 (Hennige et al., 
2003). In mice, systemic failure of IRS2 causes peripheral insulin resistance followed by β 
cell failure and diabetes (Hennige et al 2003). IRS2 protects β cells from destruction by 
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streptozotocin and improves function in isolated β cells used in transplantation (Hennige et al 
2003). Upregulation of IRS2 in β cells may help in treatment of diabetes (Hennige et al 
2003). 
1.4.4 Phosphatidylinositol 3-kinase (PI3K) signalling  
PI3K is a heterodimetric lipid kinase with important functions in metabolic, cell growth, 
proliferation, differentiation and mitogenic actions of insulin (Foukas and Shepherd, 2004). 
PI3K comprises a heterodimer between the p110 catalytic subunit and p85 regulatory subunit 
with two SH2 domains that bind to phosphotyrosine motifs on the tyrosine kinase receptor or 
substrate (Foukas and Shepherd, 2004). The family is divided into three classes (I-III) 
(Foukas and Shepherd, 2004). The insulin sensitive tissues that include skeletal muscle, liver 
and adipose tissue express variations of regulatory subunits such as p50α and p55α (Chen et 
al., 2004). IRS1 and IRS2 dock with p85 regulatory subunits that activate the p110α catalytic 
subunits (Chen et al., 2004). PtdIns(4,5)P2 is phosphorylated on the 3-OH position of the 
inositol ring to produce PtdIns(3,4,5)P3 and formation of this lipid recruits Akt and protein 
kinase C (PKC) (Chen et al., 2004). The insulin action of PI3K is impaired in skeletal muscle 
from obese insulin resistant and T2D patients (Krook et al., 2000; Cusi et al., 2000).  
PI3K is involved in insulin stimulated glucose uptake, basal glucose transporter recycling and 
phosphorylation of other intracellular second messengers (O'Brien et al., 2008). The 
association of p85 with IRS1 is an indirect marker of insulin stimulated PI3K activation and 
therefore insulin sensitivity (LeRoith et al., 1995; Rordorf-Nikolic et al., 1995; White, 
1997).The catalytic p110α subunit plays a critical role in hepatic insulin/PI3K signalling and 
is required for normal glucose and lipid homeostasis (Sopasakis et al., 2010). A lack of 
p110α results in impaired insulin signalling with a decrease in activation of downstream 
molecules including Akt (Sopasakis et al., 2010).  
1.4.5 Biological actions of insulin in metabolism  
1.4.5.1 Glucose uptake 
IR activation leads to the phosphorylation of cannabinoide receptor type 1 (Cbl), which is 
associated with the adaptor protein, catabolite activator protein (CAP) following 
phosphorylation of the Cbl-CAP complex and translocation to lipid rafts in the plasma 
membrane (Saltiel and Kahn 2001; Gupte and Mora 2006). Cbl then interacts with the 
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adaptor protein, chicken tumor virus no. 10 (CT10) regulator of kinase (Crk) that is 
constitutively associated with the Rho-family guanine nucleotide exchange factor, C3G 
(Gupte and Mora 2006). C3G in turn activates members of the guanosine triphosphate (GTP)-
binding protein family, TC10, which promotes GLUT4 translocation to the plasma membrane 
(Saltiel and Kahn 2001, Lizcano and Alessi 2002). Glucose is then taken up into the insulin 
sensitive tissues for metabolism and/or storage.  
1.4.5.2 Regulation of lipid synthesis  
Insulin promotes the uptake of FFA and the synthesis of lipids whilst inhibiting lipolysis. 
Lipid synthesis requires an increase in the transcription factor, steroid regulatory element 
binding protein (SREBP) (Shimomura et al., 1999). Insulin inhibits lipid metabolism by 
decreasing the cellular concentrations of cAMP by activating a cAMP specific 
phosphodiesterase in adipocytes (Kitamura et al., 1999). 
1.4.5.3 Protein synthesis  
Insulin stimulates amino acid uptake into cells, inhibits protein degradation and promotes 
protein synthesis (Saltiel and Kahn 2001). Under basal conditions the constitutive activity of 
glycogen synthase kinase (GSK3) leads to the phosphorylation and inhibition of a guanine 
nucleotide exchange factor, eIF2B, which regulates the initiation of protein translation 
(Asnaghi et al., 2004). Therefore, upon receiving an insulin signal, inactivation of glycogen 
synthase kinase 3 GSK3 by Akt leads to the dephosphorylation of eIF2B thereby promoting 
protein synthesis and the storage of amino acids (Lizcano and Alessi, 2002). Akt also 
activates mammalian target of rapamycin (mTOR) that promotes protein synthesis through 
p70 ribosomal S6 kinase (p70s6k) and inhibition of eIF-4E binding protein (4E-BP1) 
(Asnaghi et al., 2004). 
1.4.6 Insulin resistance 
1.4.6.1 Skeletal muscle insulin signalling and resistance 
Skeletal muscle is the major site for insulin stimulated glucose uptake (Lin and Sun, 2010; 
Abdul-Ghani and DeFronzo, 2010). Approximately 75% of insulin stimulated glucose uptake 
occurs in the skeletal muscle (Lin and Sun, 2010). Skeletal muscle utilises both glucose and 
FFA as energy sources (Abdul-Ghani and DeFronzo, 2010). Plasma insulin concentration is 
the co-factor for glucose uptake in skeletal muscle and suppresses lipolysis (Abdul-Ghani and 
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DeFronzo, 2010). During fasting, skeletal muscle glucose uptake is low and plasma FFA 
concentrations are increased; FFA therefore serve as the main energy source during fasting 
(Abdul-Ghani and DeFronzo, 2010). T2D patients may have impaired insulin stimulated 
tyrosine phosphorylation of IRS1 in skeletal myocytes that may not be related to a decrease 
in protein expression of IRS1 (Lin and Sun 2010). Similar observations were evident at the 
level of PI3K in fatty obese rats (Asano et al., 2007). IR and IR protein family dysregulation 
is the common feature of insulin resistance in skeletal muscle. This dysregulation may 
include TNFα mediated and kinase mediated serine/threonine phosphorylation, proteasome 
mediated degradation and phosphatase mediated phosphorylation, all resulting in impaired 
glucose transport in skeletal myocytes. Excessive intake of a palatable cafeteria (but low fat) 
diet induces obesity and insulin resistance both at whole body and skeletal muscle levels 
(Brandt, De, Richter, and Hespel, 2010). G-protein coupled receptor kinase 2 (GRK2) is a 
key modulator of insulin sensitivity in vivo (Garcia-Guerra et al., 2010). In cultured 
myoblasts and adipocytes, increased GRK2 levels inhibited insulin stimulated glucose uptake 
and signalling in a kinase activity independent manner by mechanisms involving the 
formation of dynamic GRK2/IRS1 complexes (Garcia-Guerra et al 2010). 
1.4.6.2 Hepatic insulin signalling and resistance 
In the liver, insulin regulates fasting glucose concentrations by inhibiting hepatic glucose 
production and stimulating glycogen synthesis. Glycogenolysis and gluconeogenesis are two 
different mechanisms involved in hepatic glucose production (Weickert and Pfeiffer, 2006). 
Glycogenolysis produces glucose in a relative short period within several hours of fasting 
(Weickert and Pfeiffer, 2006). Glycogenolysis is then suppressed by insulin after 1-2 hours 
after food intake (Weickert and Pfeiffer, 2006). During longer periods of fasting, the liver 
glycogen stores become depleted and gluconeogenesis kicks in by producing glucose from 
precursors such as pyruvate, lactate, glycerol and glucogenic amino acids (Weickert and 
Pfeiffer, 2006).  
At the molecular level, the IRS2/PI3K pathway is the major signal transduction pathway in 
the liver; abnormal IRS2 signalling is closely associated with hepatic insulin resistance 
(Valverde et al., 2003). In the liver, insulin also stimulates glycolysis, glycogen synthesis and 
the synthesis of long chain fatty acids while suppressing lipolysis (Rebrin et al., 1996). When 
the amount of p85α or p85β was increased in the liver of obese and diabetic ob/ob mice, 
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glucose tolerance was substantially increased and blood glucose concentrations reduced to 
normoglycaemic levels (Park et al., 2010). Tyrosine phosphorylation of IRβ, IRS1, IRS2 and 
the interactions between IRS1 or IRS2 and PI3K declined significantly in hepatic 
ischemia/reperfused rats suggesting that insulin signalling was impaired after hepatic 
ischemia/reperfusion (Liu et al., 2008). Hepatic ischemia/reperfusion inhibited insulin 
secretion and induced insulin resistance via reduced tyrosine phosphorylation of IRβ, IRS1, 
IRS2 and the interactions between IRS and PI3K in rats (Liu et al., 2008).  
1.5. Aspalathus linearis (rooibos) 
1.5.1 Taxonomy  
Rooibos tea is a popular South African herbal tea and is derived from Afrikaans translated as 
red bush. Rooibos tea is produced from the leaves of the indigenous South African Cape 
fynbos plant called Aspalathus linearis (Figure 1.4) (Beltran-Debon et al., 2011). Aspalathus 
linearis is a member of the family Fabaceae under the tribe Crotalaria (Joubert et al., 2008). 
Rooibos grows naturally in certain areas in the Western Cape Province of South Africa 
(Beltran-Debon et al., 2011). 
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Figure 1.4: Aspalathus linearis (rooibos) 
 
 
1.5.2 History and the discovery of rooibos  
In 1771, the Swedish botanist Carl Thunberg reported that the South African Khoisan tribe 
drank tea from a “good plant” (rooibos) for health purposes (Figure 1.4) (Joubert et al., 
2008). Rooibos was also later discovered by Dutch settlers as a cheap alternative to black tea 
imported from China and India. In the 1900s, the Russian settler and tea tradesman Benjamin 
Ginsberg developed an interest in rooibos brewing (Joubert et al., 2008) and applied the 
method of traditional Chinese fermenting of Keemun tea.  
In recent years, green tea and herbal teas have gained popularity due to their health 
promoting, particularly antioxidant, properties. Currently rooibos tea consumption has 
gradually increased since its introduction to the domestic market in 1904 by Ginsberg 
(Joubert et al., 2008). In 2010, rooibos tea secured 23% of the South African tea market 
exceeding 500 tons (Joubert and de Beer, 2012). Rooibos tea is estimated to be consumed in 
10.9 million households (Joubert et al., 2008) 
1.5.3 Major chemical constituents of rooibos  
Flavonoids hold a remarkable range of biochemical and pharmaceutical properties that 
include anti-inflammatory, anti-oxidant, anti-carcinogenic and anti-thrombotic properties 
(Snijman et al., 2007). Rooibos is the only known natural source of a C-C linked 
dihydrochalcone glucoside, aspalathin and a cyclic dihydrochalcone, aspalinin (Joubert et al., 
2008). These rare compounds are unique to rooibos. Nothofagin, a 3-dehydroxy 
dihydrocholcone glucoside, has previously been shown to be present in Nothofagus fusca 
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(heartwood) and is the second most abundant flavonoid in rooibos after aspalathin (Joubert et 
al., 2008). Rooibos also contains several C-C linked β-D-glucopyranosides, namely, the 
flavones orientin, iso-orientin, vitexin and iso-vitrxin; and the flavanones dihydro-orientin, 
dihydro-iso-orientin and hemiplorin (Joubert et al., 2008).  
1.5.4 Health benefits of rooibos  
Oxidative stress is caused by an imbalance in the production of reactive oxygen species 
(ROS) and a biological system's ability to readily detoxify the reactive intermediates or easily 
repair the resulting damage (Bansal and Bilaspuri, 2010). The elevated production of ROS 
has been suggested to play a role development of insulin resistance (Kawano et al., 2009). In 
a physiological state, ROS is removed by internal enzymatic and non-enzymatic processes 
and the failure of these two mechanisms may lead to an elevation of ROS (Ulicna et al., 
2006), thus leading to pathological complications such as insulin resistance (Ulicna et al., 
2006). Compounds that possess anti-oxidant properties can prevent insulin resistance and 
T2D by lowering oxidative stress and hence maintain glucose homeostasis (Kawano et al., 
2009). Numerous studies have been conducted on the anti-oxidant, anti-cancer and anti-
diabetic properties of rooibos tea. Rooibos tea, particularly non-fermented (green rooibos), 
contains large amounts of flavonoids and other anti-oxidants with potent scavenging for ROS 
(Bramati et al., 2003; Joubert et al., 2010). Studies have reported on the anti-oxidant activity 
of rooibos tea using different extracts and assays. Aspalathin, a major flavonoid of rooibos 
tea, improved glucose tolerance in type 2 diabetic model db/db mice (Kawano et al., 2009). 
In humans, a recent study provided clinical evidence that the chronic consumption of rooibos 
tea significantly improved several biomarkers of blood lipid status (Marnewick et al., 2011). 
Rooibos tea reduced oxidative stress by lowering lipid peroxidation and improved redox 
status in adults at risk for cardiovascular diseases (Marnewick et al., 2011).  
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Table 1.2: Major chemical constituents of rooibos (Joubert et al., 2008; Joubert et al., 
2012) 
Compound type, names and substituents General structure 
Dihydrochalcones 
Aspalathin: R1 = OH, R2 = C-β-D-glucosyl 
Nothofagin: R1 = H, R2 = C-β-D –glucosyl  
 
Cyclic dihydrochalcone 
Aspalalinin: R = C-β-D-glucosyl 
 
 
Flavanones 
Hemiphlorin: R1 = C-β-D-glucosyl, R2 = R3 = H 
(R)/(S)-eriodictyol-8-glucoside : R1 = C-β-D-glucosyl, 
R2 = H, R3 = OH 
(R)/(S)-eriodictyol-6-glucoside: R1 = H, R2 = C-β-D-
glucosyl, R3 = OH  
 
 
 
Flavones 
Orientin: R1 = C-β-D-glucosyl, R2 = R4 =OH, R3 = H 
Isoorientin: R1 = H, R2 = R4 =OH, R3 = C-β-D-
glucosyl 
Vitexin: R1 = C-β-D-glucosyl, R2 = OH, R3 = R4 = H 
Isovitexin: R1 = R4 = H, R2 = OH, R3 = C-β-D-
glucosyl 
Luteolin: R1 = R3 = H, R2 = R4 = OH 
Luteolin-7-O-glucosided: R1 = R3 = H, R2 = O-β-D-
glucosyl, R4 = OH 
Chrysoeriol: R1 = R3 = H, R2 = OH, R4 = OCH3 
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Flavonols 
Quercetin: R = H 
Isoquercitrin: R = O-β-D-glucosyl 
Hyperoside: R = O-β-D-galactosyl 
Rutin: R = O-β-D-rutinosyl 
Quercetin-3-O-β-D-robinosideg: R = O-robinosyl 
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CHAPTER 2 
STUDY AIMS  
 
2.1 Study aim  
To investigate the effects of maternal diets varying in fat content on neonatal gene and 
protein expression profiles of proximal insulin signalling factors (IRα, IRS2 and PI3K-
p110α). 
2.2 Specific objectives  
 To determine the maternal circulating total cholesterol, triglyceride and free fatty acid 
concentrations. 
 To determine the relative gene and protein expression profiles of IR, IRS2 and the 
p110 subunit of PI3K in neonatal skeletal muscle and liver. 
 To assess the therapeutic potential of Aspalathus linearis (green rooibos) on the 
programming effects of a high fat diet. 
2.3 Expected outcomes  
 Exposure to varying dietary fat content, in utero, may have differential effects on the 
expression profiles of insulin signalling factors in neonatal skeletal muscle and liver.  
 A high fat diet may programme neonatal insulin resistance characterised by reduced 
expression of proximal insulin signalling factors.  
 Aspalathus linearis supplementation may ameliorate the adverse programming effects 
of a maternal high fat diet in neonatal offspring.  
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Main study  
3.1.1 Experimental design 
The animal experiments were carried out according to the protocol approved by the Medical 
Research Council ethics committee (Ref. 07/11). Virgin Wistar rats (3 months old), weighing 
220-275 g, were individually housed and mated overnight with pregnancy confirmed by 
presence of vaginal plug(s). The pregnant rats were then randomly assigned to groups. The 
groups (n = 4 rats per group) were 10% fat (as energy) diet (control), 20% fat (as energy) diet 
(20F), 30% fat (as energy) diet (30F) and 40% fat (as energy) (40F or high fat diet) (Table 
3.1). Therefore the groups were control (10% fat diet), 20F, 30F and 40F mothers and their 
one-day-old neonatal offspring (Table 3.1). The pregnant rats had free access to food and 
water and were housed at a temperature of 22-25ºC, humidity of 45-55% and a 12 hour 
light/dark (light daily from 06h00-18h00). The rats were treated in accordance with the 
United States National Institutes of Health (NIH) guidelines for animal care and usage.  
Table: 3.1 Experimental diets 
Macronutrient Control  20F  30F  40F  
Fat (%) 10.69 20.68 31.00 40.17 
Protein (%) 15.13 15.09 15.77 15.09 
Carbohydrate (%) 
Total kcal/100g 
74.16 
453.37 
64.22 
525.51 
53.23 
554.08 
44.73 
600.81 
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    Termination (neonates) 
Weeks     -1   0   1  2   3 
   Start 
       Gestation (mothers) 
         
e0   e7    e14 
     
e20  d1 
Before pregnancy  
Gestation period  
Laboratory chow Experimental diets (Control, 20F, 30F and 40F) 
 
Food and water intake 
Body weights 
Blood collection 
Fasting glucose 
Food and water intake 
Body weights 
Blood collection 
Fasting glucose 
Fasting glucose 
Blood collection 
Tissue collection 
 
Figure 3.1 Experimental timeline  
Diets:  
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Figure 3.2 Experimental design (main study)  
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neonates 
Liver and 
 skeletal muscle 
Gene expression  
(Real-time qPCR)   
 (n = 10) 
IRα, IRS2 and  
PI3K (p110α) 
Protein expression 
(IHC and image analyses) 
(n = 6) 
IRα, IRS2 and  
PI3K (p110α) 
Mothers 
Serum lipid analyses  
 
Lipidaemia 
(Gas Chromatography, CHOD-PAP and 
GPO-PAP method) (n = 4) 
Free fatty acids, triglycerides and 
cholesterol 
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3.1.2 Maternal and neonatal blood collection  
Blood analyses were performed to determine the circulating lipid profiles in mothers and 
neonates. Pregnant rats were fasted for four hours; a volume of 0.5 ml blood was collected 
weekly from the tail vein. Blood was collected before mating, at days 7, 14 and 20 of gestation 
(e7, e14 and e20 respectively) and on the day of delivery (d1). On d1, the mothers were 
euthanized and blood was immediately collected from the aorta with 6 ml syringes and 
transferred to tubes (BD Vacutainer blood collection tubes, BD, New Jersey, USA) for the 
determination of serum insulin, glucagon, free fatty acid (FFA; total and individual), total 
triglyceride and total cholesterol concentrations. Neonatal offspring were euthanized on postnatal 
day one (d1). Trunk blood from the litter of neonates per dam was pooled for sampling (a 
minimum of 500 l per sample) for each experimental group.  
3.1.3 Determination of serum cholesterol and total triglyceride concentrations 
In mothers, serum triglyceride concentrations were determined by the GPO-PAP method with 
the enzymatic colorimetric test for triglycerides with clearing factor (LCF) and measured in an 
autohumalyzer A5 (Human Biochemical and Diagnostics, Wiesbaden, Germany). Serum total 
cholesterol concentrations were determined by the CHOD-PAP method with the enzymatic 
colorimetric test for cholesterol with LCF and measured with an autohumalyzer A5 (Human 
Biochemical and Diagnostics).  
3.1.4 Determination of total free fatty acids (FFA) concentrations  
FFA were extracted from maternal serum samples. A volume of 200 µl of serum was added to 3 
ml methanol + butylated hydroxytoluene and 50 µl of internal standard for quantification of FFA 
then vortex mixed for 15 seconds. A volume of 6 ml of chloroform was added and the mixture 
was centrifuged at 2500 rpm for 10 min. The lower chloroform layer was removed and re-
suspended into a clean test tube. The chloroform layer was then evaporated completely in a water 
bath at 37°C for 15 min. When dried completely, 2 ml of transmethylating reagent was added. 
Hexane (HPLC grade) was used for FFA extraction. The hexane phase was re-suspended into a 
clean test tube and evaporated completely in a water bath at 37°C. Carbon disulphide was added 
to re-dissolve lipids and injected in gas chromatography.  
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3.1.5 Relative PCR quantification 
3.1.5.1 Housekeeping gene selection  
In skeletal muscle, β-actin and TBP displayed the most stable expression in rat gastrocnemius 
and soleus muscles (Yuzbasioglu et al., 2010). In the liver, β-actin and TATA-binding protein 
(TBP) were the most stable housekeeping genes in the regenerating mouse model (Tatsumi et al., 
2008). Therefore β-actin and TBP were selected as housekeeping genes for qRT-PCR analyses. 
3.1.5.2 RNA preparation and quantitative RT-PCR 
Skeletal muscle and liver were harvested; snap frozen in liquid nitrogen and stored at -80C. 
Total RNA was isolated from 100 mg of skeletal muscle and liver using QIAzol lysis reagent 
(Qiagen, Hilden, Germany). RNA was purified using RNeasy mini kits according to the 
manufacturer’s instructions (Qiagen, Hilden, Germany). The RNA samples were then treated 
with TURBO DNA-free kits (Ambion, Applied Biosystems, Foster City, California, USA) to 
remove any contamination with genomic DNA. The RNA yield and quality were assessed using 
a nanodrop spectrophotometer and RNA integrity was assessed using an Agilent Bioanalyser and 
Agilent RNA 600 nano kit (Agilent technologies, Santa Clara, CA, USA). A total of 1 µg total 
RNA per sample constituted to 10 µl with sterile water was reverse transcribed into first strand 
complementary DNA (cDNA) using a high capacity cDNA kit (Applied Biosystems). A positive 
control was prepared by constituting 1 µg of Amb rat liver RNA control template to 10 µl with 
sterile water and the negative control by adding 10 µl of sterile water to a PCR tube. The PCR 
tubes were prepared in duplicate and placed in a thermal cycler (Applied Biosystems 2720). 
Taqman probes for insulin receptor, insulin substrate 2 and PI3K were used along with the 
housekeeping genes β-actin mRNA and TBP mRNA. Quantitative PCR was performed using the 
applied Biosystems 7500 RT-PCR system and the Power SYBER Green PCR kit (Applied 
Biosystems) using a cycler programme consisting of an activation step of 10 min at 95°C, 40 
cycles with a 15 second denaturing step at 95ºC and 1 min at 60ºC for annealing and extension. 
Data analysis was performed with 7500 SDS software to run a relative quantification plate and to 
analyse the RT-PCR results. The relative mRNA expression was expressed as the quantity mean 
of IR, IRS2 and PI3K divided by an average quantity mean of β-actin and TBP. 
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3.1.6 Tissue collection and processing for immunohistochemistry (IHC) 
Skeletal muscle and liver were collected in 10% buffered formalin and processed in paraffin wax 
for IHC followed by image analysis.  
3.1.7 IHC 
Neonatal skeletal muscle and liver were fixed in 10% buffered formalin (pH 7.4) for 12 hours, 
processed using Leica TP11020 Automatic Tissue Processor (Leica, Wetzlar, Germany) and 
embedded in paraffin wax. Sections of 4 µm thick were cut using a Leica RM2125 RT rotary 
microtome (Leica) and mounted onto APES-coated microscope glass slides. Serial wax sections 
of skeletal muscle and liver were rehydrated through xylene, alcohol and distilled water. The 
sections were then incubated in 3% hydrogen peroxide (H2O2) for 10 minutes at room 
temperature, placed in heat resistant staining jars filled with 1.01 M citrate buffer (pH 6.0) and 
cooked in a Dako Pascal pressure chamber (Dako cytomation, DK-2600, Glostrup, Denmark) 
(125°C for 3 minutes; 90°C for 30 seconds). All sections were then jet washed with 50mM Tris 
buffer (pH 7.2) for 5 minutes at room temperature. 
Sections immunostained for IRα (1:500; Abcam, Cambridge, UK) were blocked with normal 
goat serum for 20 minutes, incubated with IRα overnight at 4°C then incubated in 1:200 
biotinylated anti-rabbit IgG (Vector, Laboratories, Burlingame, CA, USA) for 30 minutes. 
Sections immunostained for IRS2 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
were blocked with normal goat serum for 20 minutes, incubated with insulin receptor substrate 2 
overnight at 4°C then incubated in 1:200 biotinylated anti-rabbit IgG (Vector, Laboratories) for 
30 minutes. Sections immunostained for PI3K-p110α antibody (1:10; Cell Signalling 
Technology, Danvers, MA, USA) were blocked with normal horse serum for 20 minutes, 
labelled with PI3K-p110α overnight at 4°C, then incubated in 1:200 biotinylated anti-rabbit IgG 
(Vector Laboratories) for 30 minutes. All sections were then washed with 50 mM Tris buffer (pH 
7.2) for 5 minutes and incubated with ABC complex (Vector Laboratories) for 60 minutes at 
room temperature, washed in 50 mM tris buffer (pH 7.2) for 5 minutes and stained with 0.05% 
diaminobenzadine containing 0.01% H2O2 for 5-10 minutes at room temperature. All sections 
were counterstained with haematoxylin for 2 minutes, left to dry and mounted with entellan.  
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3.1.8 Image analysis  
Images were captured with a Nikon-DS Fi1 digital camera mounted onto an Olympus BX50 light 
microscope (Olympus, Hamburg, Germany). All images were captured at X20 and stored in tiff 
format at a final resolution of 1024 X 796. Stored images were analysed with Leica QwinPro 
V3.0 image analysis software (Leica Microsystems GmbH, Wetzlar, Germany) to differentiate 
between immunohistochemical positive and negative areas using RGB colour thresholding. 
Immunoreactivity was expressed as the area of immunostained target protein, namely, IRα, IRS2 
and PI3K-p110α, in the skeletal muscle and liver per total tissue area. This generated a relative 
quantification as a percentage.  
3.2 Pilot study  
3.2.1 Mothers  
3.2.1.1 Experimental design 
The pilot study was separately approved by the Medical Research Council ethics committee 
(Ref. 07/11). Twenty virgin female Wistar rats (3-month-old) with an average weight of 234.75 g 
(weight range of 205 - 252 g) were individually housed and mated overnight with pregnancy 
confirmed by presence of vaginal plug(s). The pregnant rats were then randomly assigned to 
groups (n = 5 rats per group), namely: 10% fat (as energy) diet (control), 10% fat (as energy) diet 
supplemented with Aspalathus linearis enriched aqueous extract (control + Al), 40% fat (as 
energy) diet (40F; high fat diet) and a 40% fat (as energy) diet supplemented with Aspalathus 
linearis enriched aqueous extract (40F + Al) (Table 3.2). Therefore the groups were control 
(10% fat diet), control + Al, 40F (40% fat diet) and 40F + Al mothers and their neonatal 
offspring (Table 3.2). The mothers had free access to food and water and were housed at a 
temperature of 22-25ºC, humidity of 45-55% and a 12 hour light/dark (light daily from 06h00-
18h00). The rats were treated in accordance with the United States NIH guidelines for animal 
care and usage.  
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Table 3.2: Experimental groups  
Group Diet   Nomenclature 
1 10% fat    Control 
2 10% fat + Aspalathus linearis   Control + Al 
3 40% fat   HFD  
4 40% fat + Aspalathus linearis   HFD + Al 
 
3.2.1.2 Aspalathus linearis extraction and formulation 
Powdered green rooibos extract was obtained from the Raps Foundation (Freising-
Weihenstephan, Germany). The extract is an aspalithin-enriched solvent-based extract prepared 
according to a patented process (Grüner-Richter et al., 2008). The basic preparation entailed 
extraction of the plant material with an 80% ethanol-water mixture at room temperature, 
filtration and vacuum-drying. The powder was then extracted with ethyl acetate to reduce the 
chlorophyll content, filtered and vacuum-dried. 
 
        
Figure 3.3: HPLC chromatogram of an unfermented green rooibos 80% ethanol-water 
extract at 288 nm (A) and at 350 nm (B) [1, enolic phenylpyruvic acid-2-O-glucoside; 2, iso-
orientin; 3, orientin; 4, aspalathin; 5, quercetin-3-O-robinobioside; 6, vitexin; 7, hyperoside; 8, 
rutin; 9, isovitexin; 10, isoquercitrin; 11, nothofagin] (Muller et al., 2012). 
A B 
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Table.3.3 Chemical characterization of Aspalathus linearis (Muller et al., 2012) 
Compound Concentration in g/100 g Aspalathus linearis 
extract 
PPAG 0.491 
Aspalathin 18.440 
Nothofagin 1.292 
Iso-orientin 2.054 
Quercetin-3-O-robinobioside 1.053 
Vitexin 0.270 
Hyperoside 0.266 
Rutin 0.536 
IsoVitexin 0.389 
Isoquercitrin 0.377 
3.2.1.3 HPLC chromatography and phenolic acid content of a Aspalathus linearis extract  
The unfermented Aspalathus linearis water extract revealed that aspalathin (peak 4) had the 
highest peak at 280 nm (Figure 3.3A) and at 350 nm iso-orientin (peak 2), orientin (peak 3) and 
aspalathin (peak 4) had the highest peaks, in decreasing order (Figure 3.3B). Unfermented 
rooibos also had the highest concentration of aspalathin followed by iso-orientin in g/100g of 
green rooibos extract (Table 3.3) (Muller et al., 2012).  
3.2.1.4. Extract preparation and administration  
The extract was orally administered to the 10% (control) and 40% (40F or HFD) diet groups via 
jelly cubes according to an established Diabetes Discovery Platform SOP for administering 
treatment to rats. Aspalathus linearis enriched aqueous extract was obtained from the 
Agricultural Research Council (ARC). The extract was added and dissolved in jelly. Jelly stock 
comprised 80 g jelly, 7 g gelatin (Pick and Pay, Rosmead Avenue, Kenilworth, South Africa) 
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and 300 ml of boiled distilled water. The Aspalathus linearis dose of 150 mg/kg per day was 
transferred into ice cube trays corresponding to the experimental rat numbers. Quality control 
procedures were to maintain a clean working environment, servicing pipettes and calibrating 
scales. The Aspalathus linearis extract was freshly prepared daily to prevent the degradation of 
unstable compounds, bacterial and fungal contamination.  
Table 3.4: Experimental outline 
Time Phase Diet  
1 week  prior to mating (e-7 
to e-1) 
Habituation: jelly habituation Control 
Weeks 1-3 gestation period 
(e0-e21) 
Experiments: 
 Pregnancy confirmed  
 Mothers assigned to 
diets 
 Maternal food intake 
 Blood collection  
Control and high fat 
diets 
End of week 3 (delivery; 
d1) 
Terminations: 
 Neonatal blood and 
tissue collection 
 Maternal blood and 
tissue collection  
Control and high fat 
groups 
 
3.2.1.3 Maternal body weight and food intake 
Maternal body weights were recorded prior to mating (e0), on days 7, 14 and 20 of gestation (e7, 
e14 and e20) and on the day of delivery (d1). Food consumption was recorded daily.  
3.2.1.4 Maternal blood collection  
Pregnant rats were fasted for four hours and 0.5 ml blood was collected a week prior to mating 
(e-7), e0, e7, e14, e20 and d1. Further, on d1 the rats were terminated and maternal blood was 
immediately collected from the aorta using 6 ml syringe and transferred to BD Vacutainer blood 
collection tubes (BD, Franklin Lakes, NJ, USA) for the determination of serum insulin, 
glucagon, FFA, total triglyceride and total cholesterol concentrations.  
 
 
 
 
  
32 
 
3.2.1.5 Maternal blood glucose concentrations  
Four hour fasted blood glucose concentrations were measured weekly (e0, e7, e14, e20 and d1). 
A drop of blood was used to determine maternal blood glucose concentrations using a One 
Touch Ultra glucometer (Life Scan, Milpitas, CA, USA).   
3.2.1.6 Serum insulin and glucagon concentrations  
Radioimmunoassays were applied to determine the serum insulin (
125
I-labelled rat anti-insulin; 
Linco, St. Charles, MO, USA) and glucagon (
125
I-labelled rat anti-glucagon; Linco) 
concentrations. I-labelled samples were counted in a Perkin Elmar 1470 automatic gamma 
counter (Perkin Elmar, Turku, Finland). 
3.2.2 Neonates  
3.2.2.1 Anthropometric measurements  
At birth, all neonates were removed from the mothers and separated according to gender. The 
anthropometric measurements were conducted within 24 hours of birth (postnatal day 1). 
Neonatal body weights were measured on a calibrated scale. Neonatal body dimensions were 
measured with a measuring tape. The head length (from the tip of the snout to the base of the 
skull), head width (distance from ear to ear), head circumference, crown-rump (distance from the 
top of the head to the rump) and crown-tail (distance from the top of the head to the tip of the 
tail) were recorded.  
3.2.2.2 Neonatal blood collection  
One-day-old neonates were removed from mothers and fasted for four hours. For neonatal blood 
collection, neonates were decapitated and trunk blood was collected from each neonatal group. 
Trunk blood from each litter per mother was pooled for sampling (a minimum of 500 µl per 
sample) for each experimental group. The neonatal blood samples were separated according to 
gender.  
 
 
 
 
  
33 
 
3.2.2.3 Neonatal blood glucose concentrations 
Neonatal glucose concentrations were measured on the day of birth. A drop of blood (trunk 
blood) was used to determine blood glucose concentrations with a glucometer (Life Scan).  
3.2.2.3 Neonatal serum insulin concentrations 
All neonatal blood samples were collected and centrifuged at 4000 rpm for 15 minutes and 
stored at -20°C for analysis. Radioimmunoassays were applied to determine the serum insulin 
concentrations. I-labelled samples were counted in a Perkin Elmar 1470 automatic gamma 
counter (Perkin Elmar, Turku, Finland). 
3.2.2.4 Homeostasis model assessment for insulin resistance (HOMA-IR) 
HOMA-IR was calculated as HOMA-IR = [Fasting glucose (mmol/L)/Fasting insulin 
(mU/L)]/22.5 (Lisa et al., 2009). 
3.3 Statistical analysis  
All data are presented as means ± SEM. Comparisons of groups were performed by One-way 
ANOVA followed by Bonnferroni’s post-test using GraphPad Prism 5 software (GraphPad 
Software, San Diego, CA, USA). Significance was established at p < 0.05. 
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CHAPTER 4 
RESULTS 
4.1 MAIN STUDY  
4.1.1 Mothers  
4.1.1.1 Maternal total triglyceride, cholesterol and fatty acid concentrations 
Serum total triglyceride, cholesterol and fatty acid concentrations were not significantly different 
before gestation, during gestation or on the day of delivery amongst the groups (Table 4.1). 
 
Table 4.1 Maternal total serum triglyceride, cholesterol and fatty acid concentrations 
 Control 20F 30F 40F 
 
Triglycerides (mmol/l) 
    
    Before pregnancy 1.49 ± 0.28 1.16 ± 0.16 1.27 ± 0.20 1.13 ± 0.14 
    Day 7 of gestation 1.20 ± 0.12  0.95 ± 0.17  1.24 ± 0.29  1.15 ± 0.16   
    Day 14 of gestation 1.57 ± 0.20 1.31 ± 0.50 1.64 ± 0.20 1.11 ± 0.04 
    Day 20 of gestation 1.93 ± 0.26 1.36 ± 0.41 3.38 ± 0.68 4.32 ± 1.06 
    Day of delivery 0.82 ± 0.17 1.22 ± 0.42 0.83 ± 0.31 0.81 ± 0.10 
Cholesterol (mmol/l)     
    Before pregnancy 1.11 ± 0.11 1.17 ± 0.09 1.38 ± 0.08 1.32 ± 0.12 
    Day 7 of gestation 1.49 ± 0.16 1.16 ± 0.08 1.53 ± 0.07 1.36 ± 0.10 
    Day 14 of gestation 0.98 ± 0.14 0.92 ± 0.08 1.22 ± 0.17 0.82 ± 0.08 
    Day 20 of gestation 1.59 ± 0.12 1.24 ± 0.11 1.82 ± 0.16 1.50 ± 0.32 
    Day of delivery 2.36 ± 0.49 1.58 ± 0.07  1.74 ± 0.08 2.03 ± 0.27 
     
     
     
 
Table 4.1 continued on page 35  
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Data are means ± SEM (n = 5). Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.
 
 
All groups were compared with One-way ANOVA. 
 
4.1.1.2 Maternal total saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), 
omega 3 polyunsaturated fatty acids (n-3 PUFA) and omega 6 polyunsaturated fatty acids 
(n-6 PUFA) 
On the day of delivery, both 30F and 40F mothers had reduced total SFA compared to control 
mothers (Table 4.2). On the day of delivery, 40F mothers had increased total MUFA compared 
to 20F and 30F mothers (Table 4.2). At day 7 of gestation, total n-3 PUFA were reduced in 30F 
and 40F mothers compared to control mothers; further, the 30F mothers had reduced total n-3 
PUFA compared to 20F mothers (Table 4.2). At day 7 of gestation, there was an increase in total 
n-6 PUFA in 30F mothers compared to control mothers (Table 4.2).  
 
 
 
 
 
 
 
 
 
     
 Control 20F 30F 40F 
Fatty acid (µg/ml)     
    Before pregnancy 1035 ± 209 8734 ± 149 881 ± 80 1530 ± 540 
    Day 7 of gestation 1465 ± 66 1695 ± 350 1291 ± 92 1247 ± 92 
    Day 14 of gestation 1071 ± 145 1537 ± 95 1565 ± 365 1690 ± 181 
    Day 20 of gestation 2208 ± 162 1887 ± 247 1543 ± 494 2627 ± 196 
    Day of delivery 1340 ± 79 1255 ± 92. 1424 ± 132 1467 ± 141 
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Table 4.2 Maternal total SFA, MUFA, n-3 PUFA and n-6 PUFA compositions (%) 
 Control 20F 30F 40F 
SFA (%)     
    Before pregnancy 49.49 ± 2.74 46.43 ± 1.40 58.82 ± 4.334 61.67 ± 3.53 
    Day 7 of gestation 39.62 ± 0.70 40.78 ± 1.46 42.68 ± 0.92 42.89 ± 1.53 
    Day 14 of gestation 41.95 ± 1.50 38.76 ± 1.41 53.31 ± 7.32 43.45 ± 4.14 
    Day 20 of gestation 36.43 ± 1.28 38.50 ± 2.15 43.54 ± 2.44 36.85 ± 2.33 
    Day of delivery 43.17 ± 0.84 40.44 ± 0.16 39.20 ± 0.30
*
 38.37 ± 1.22
*
 
MUFA (%)     
    Before pregnancy 20.41 ± 1.90 16.73 ± 1.32 12.08 ± 1.65 16.42 ± 5.80 
    Day 7 of gestation 26.77 ± 1.21 22.96 ± 2.76 18.54 ± 0.81 19.99 ± 1.11 
    Day 14 of gestation 26.99 ± 1.58 25.40 ± 1.86 20.81 ± 2.46 25.01 ± 1.05 
    Day 20 of gestation 29.95 ± 1.70 27.75 ± 0.69 24.67 ± 3.68 26.93 ± 1.81 
    Day of delivery 
n- 3 PUFA (%) 
11.96 ± 0.60 10.39 ± 0.42 10.69 ± 0.99 14.78 ± 0.96
†‡
 
    Before pregnancy 2.33 ± 0.40 3.40 ± 0.50 2.93 ± 0.17 3.33 ± 0.63 
    Day 7 of gestation 4.52 ± 0.21 4.16 ± 0.11 2.76 ± 0.15
*†
 3.46 ± 0.19
*
 
    Day 14 of gestation 5.51 ± 0.59 4.62 ± 0.29 2.42 ± 0.58 3.83 ± 0.79 
    Day 20 of gestation 5.61 ± 0.66 5.45 ± 0.97 3.18 ± 0.67 5.45 ± 0.28 
    Day of delivery 6.23 ± 0.42 7.08 ± 0.28 5.74 ± 0.44 5.87 ± 0.62 
n- 6 PUFA (%)     
    Before pregnancy 27.76 ± 4.19 33.44 ± 2.51 26.17 ± 3.46 26.73 ± 2.33 
    Day 7 of gestation 29.09 ± 0.67 32.10 ± 1.32 36.02 ± 0.96
*
 33.67 ± 2.06 
    Day 14 of gestation 25.55 ± 0.79 31.22 ± 1.93 23.46 ± 4.57 27.73 ± 3.06 
    Day 20 of gestation 28.02 ± 2.32 28.31 ± 1.86 28.61 ± 3.49 30.78 ± 0.25 
    Day of delivery 28.02  ± 2.32 28.31 ± 1.86 28.61 ± 3.49 30.78 ±0.25 
Data are means ± SEM (n = 5). Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.
 
 
*
p < 0.05 vs. Control, 
†
p < 0.05 vs. 20F, 
‡
p < 0.05 vs. 30F. All groups were compared with One-
way ANOVA.  
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4.1.1.3 Individual SFA and MUFA percentages  
SFA 
On day 7 of gestation, 30F mothers had increased behenic acid (22:0) compared to 20F mothers 
(Table 4.3). On day 14 of gestation and on the day of delivery, 40F mothers had reduced behenic 
acid (22:0) compared to 30F mothers.  
 
Table 4.3 Maternal serum saturated fatty acids compositions (%)  
 Control 20F 30F 40F 
  Myristic acid (14:0)      
    Before pregnancy 4.01 ± 2.10 2.21 ± 1.79 6.75 ± 3.19 9.07 ± 2.62 
    Day 7 of gestation 0.83 ± 0.10 1.08 ± 0.22 1.09 ± 0.20 0.89 ± 0.04 
    Day 14 of gestation 0.76 ± 0.12 0.86 ± 0.10 7.41 ± 2.97 3.10 ± 1.80 
    Day 20 of gestation 0.75 ± 0.12 1.17 ± 0.16 1.45 ± 0.61 1.88 ± 0.45 
    Day of delivery 0.37 ± 0.10 0.24 ± 0.07 0.49 ± 0.11 0.51 ± 0.05 
  Palmitic acid (16:0)      
    Before pregnancy 24.75 ± 0.96 23.38 ± 1.29 24.46 ± 2.90 23.52 ± 1.97 
    Day 7 of gestation 18.82 ± 0.79 18.85 ± 1.08 18.24 ± 0.30 18.16 ± 0.88 
    Day 14 of gestation 21.43 ± 0.77 19.03 ± 1.41 24.20 ± 2.73 20.25 ± 1.57 
    Day 20 of gestation 19.01 ± 0.01 19.27 ± 1.52 22.13 ± 1.79 18.02 ± 1.04 
    Day of delivery 21.72 ± 0.31 19.10 ± 0.56 19.14 ± 1.21 19.26 ± 0.61 
Stearic acid (18:0)      
    Before pregnancy 19.56 ± 0.96 20.71 ± 1.15 25.69 ± 0.92 21.16 ± 2.13 
    Day 7 of gestation 18.65 ± 0.48 19.72 ± 1.77 21.67 ± 1.04 22.40 ± 22.40 
    Day 14 of gestation 18.67 ± 1.38 18.04 ± 0.25 20.53 ± 1.68 18.99 ± 0.99 
    Day 20 of gestation 15.70 ± 1.11 17.07 ± 0.71 18.59 ± 0.48 16.22 ± 1.74 
    Day of delivery 19.80 ± 0.90 19.92 ± 0.49 18.33 ± 1.10 17.68 ± 0.62 
     
     
Table 4.3 continued on page 38 
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 Control 20F 30F 40F 
Arachidic acid (20:0)      
    Before pregnancy 0.33 ± 0.03 0.30 ± 0.05 0.31 ± 0.06 0.40 ± 0.17 
    Day 7 of gestation 0.32 ± 0.03 0.33 ± 0.10 0.34 ± 0.04 0.32 ± 0.08 
    Day 14 of gestation 0.42 ± 0.11 0.21 ± 0.06 0.42 ± 0.06 0.54 ± 0.18 
    Day 20 of gestation 0.31 ± 0.09 0.40 ± 0.07  0.44 ± 0.05 0.38 ± 0.18 
    Day of delivery 0.08 ± 0.01 0.15 ± 0.06 0.11 ± 0.02 0.18 ± 0.10 
Behenic acid (22:0)      
    Before pregnancy 1.11 ± 0.70 0.41 ± 0.03 0.37 ± 0.02 0.32 ± 0.05 
    Day 7 of gestation 0.28 ± 0.01 0.26 ± 0.05 0.41 ± 0.03
†
 0.36 ± 0.04 
    Day 14 of gestation 0.23 ± 0.01 0.18 ± 0.02 0.24 ± 0.02 0.18 ± 0.003
‡
 
    Day 20 of gestation 0.23 ± 0.02 0.22 ± 0.02 0.33 ± 0.08 0.19 ± 0.01 
    Day of delivery 0.31 ± 0.02 0.29 ± 0.02 0.35 ± 0.04 0.21 ± 0.003
‡
 
Data are as means ± SEM (n = 5). Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.
 
 
†
p < 0.05 vs. 20F, 
‡
p < 0.05 vs. 30F. All groups were compared with One-way ANOVA. 
 
MUFA 
On day 14 of gestation, the 30F and 40F mothers had reduced palmitoleic acid (16:1 n-7) 
compared to control mothers (Table 4.4). On the day of delivery, 40F mothers had increased 
oleic acid (18:1 n-9) compared to 20F and 30F mothers. On day 7 of gestation, vaccenic acid 
(18:1 n-7) was reduced in 30F and 40F mothers compared to control and 20F mothers. Further, 
on the day of delivery, vaccenic acid (18:0 n-7) was reduced in 20F, 30F and 40F mothers 
compared control mothers and in 40F mothers compared to control mothers. On day 7 of 
gestation, nervonic acid (24:1 n-9) was increased in 30F mothers compared to control mothers.  
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Table 4.4 Maternal serum monounsaturated fatty acid composition (%)  
Data are means ± SEM (n = 5). Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.
 
 
*
p < 0.05 vs. Control, 
†
p < 0.05 vs. 20F,
 ‡
p < 0.05 vs. 30F. All groups were compared with One-
way ANOVA.  
 Control 20F 30F 40F 
Palmitoleic acid (16:1 n-7)    
    Before pregnancy 1.86 ± 0.29 1.01 ± 0.09 0.84 ± 0.16 0.89 ± 0.26 
    Day 7 of gestation 2.96 ± 0.29 1.62 ± 0.66 1.41 ± 0.08 1.41 ± 0.14 
    Day 14 of gestation 3.30 ± 0.08 2.06 ± 0.46 1.10 ± 0.21
*
 1.27 ± 0.16
*
 
    Day 20 of gestation 3.76 ± 0.94 2.55 ± 0.23 1.63 ± 0.41 1.51 ± 0.26 
    Day of delivery 1.01 ± 0.12 0.66 ± 0.12 0.64 ± 0.07 0.84 ± 0.07 
Oleic acid (18:1 n-9)     
    Before pregnancy 15.65 ± 1.23 12.27 ± 1.02 8.89 ± 1.14 11.51 ± 3.80 
    Day 7 of gestation 19.94 ± 0.90 18.53 ± 2.54 15.50 ± 0.71 16.96 ± 1.15 
    Day 14 of gestation 20.30 ± 1.26 20.60 ± 1.31 17.92 ± 1.83 21.87 ± 0.82 
    Day 20 of gestation 21.69 ± 0.06 21.73 ± 0.74 19.48 ± 3.30 22.97 ± 0.47 
    Day of delivery 8.72 ± 0.63 7.79 ± 0.31 8.47 ± 1.02 12.67 ± 0.84
†‡
 
Vaccenic acid (18:1 n-7)     
    Before pregnancy 2.79 ± 0.18 2.28 ± 0.30 1.76 ± 0.37 1.76 ± 0.37 
    Day 7 of gestation 3.08 ± 0.16 2.09 ± 0.44 1.02 ± 0.07
*†
 0.97 ± 0.02
*†
 
    Day 14 of gestation 2.92 ± 0.15 2.10 ± 0.58 1.38 ± 0.50 1.48 ± 0.42 
    Day 20 of gestation 3.88 ± 0.68 2.89 ± 0.13 2.92 ± 0.08 1.93 ± 1.01 
    Day of delivery 1.63 ± 0.06 1.26 ± 0.04
*
 1.04 ± 0.09
*
 0.85 ± 0.05
*†
 
Nervonic acid (24:1 n-9)     
    Before pregnancy 0.40 ± 0.11 0.99 ± 0.26 0.73 ± 0.30 1.13 ± 0.10 
    Day 7 of gestation 0.59 ± 0.04 0.74 ± 0.10 0.94 ± 0.08* 0.76 ± 0.08 
    Day 14 of gestation 0.28 ± 0.11 0.36 ± 0.01 0.49 ± 0.09 0.36 ± 0.02 
    Day 20 of gestation 0.34 ± 0.10 0.39 ± 0.05 0.91 ± 0.46 0.33 ± 0.00 
    Day of delivery 0.65 ± 0.04 0.59 ± 0.07 0.47 ± 0.09 0.52 ± 0.07 
 
 
 
 
  
40 
 
4.1.1.4 Individual n-3 PUFA and n-6 PUFA composition (%)  
n-3 PUFA 
On day 7 of gestation, linolenic acid (18:3 n-3) was reduced in 30F and 40F mothers compared 
to control mothers (Table 4.5). On day 7 of gestation, eicosatrienoic acid (20:3 n-3) was reduced 
in 30F mothers compared to the other groups and in 20F mothers compared to control mothers 
(Table 4.5). On day 14 of gestation, eicosapentaenoic acid (20:5 n-3) was reduced in 40F 
mothers compared to control mothers whereas on the day delivery, the 40F mothers had 
increased eicosapentaenoic acid (20:5 n-3) compared to the other groups (Table 4.5). On day 14 
of gestation, docosapentaenoic acid (22:5 n-3) was reduced in 30F and 40F mothers compared to 
control mothers and remained reduced on the day of delivery in 40F mothers compared control 
mothers (Table 4.5). 
 
Table 4.5 Maternal serum n-3 polyunsaturated fatty acids compositions (%) 
 Control 20F 30F 40F 
Linolenic acid (18:3 n-3)      
    Before pregnancy 0.41 ± 0.02 0.55 ± 0.08 0.51 ± 0.13 0.80 ± 0.18 
    Day 7 of gestation 0.77 ± 0.04 0.63 ± 0.10 0.48 ± 0.04
*
 0.49 ± 0.03
*
 
    Day 14 of gestation 0.96 ± 0.14 0.53 ± 0.02 0.47 ± 0.13 0.67 ± 0.09 
    Day 20 of gestation 1.05 ± 0.49 0.75 ± 0.20 0.49 ± 0.10 1.04 ± 0.32 
    Day of delivery 0.31 ± 0.02 0.24 ± 0.02 0.28 ± 0.06 0.30 ± 0.00 
Eicosatrienoic acid (20:3 n-3)     
    Before pregnancy - 0.05 ± 0.01 0.07 ± 0.00 0.10 ± 0.03 
    Day 7 of gestation 0.07 ± 0.003 0.05 ± 0.003
*
 0.04 ± 0.00
*†§
 0.06 ± 0.03 
    Day 14 of gestation 0.07 ± 0.01 0.05 ± 0.003 0.04 ± 0.00 0.05 ± 0.01 
    Day 20 of gestation 0.06 ± 0.01 0.05 ± 0.01 0.03 ± 0.00 0.05 ± 0.01 
    Day of delivery - 0.09± 0.001 0.05 ± 0.00 0.07 ± 0.00 
     
Table 4.5 continued on page 41 
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Control 20F 30F 40F Control 
Eicosapentaenoic acid (20:5 n-3)     
    Before pregnancy 0.27 ± 0.02 0.25 ± 0.03 0.23 ± 0.02 0.24 ± 0.05 
    Day 7 of gestation 0.79 ± 0.17 0.61 ± 0.20 0.25 ± 0.03 0.29 ± 0.05 
    Day 14 of gestation 0.88 ± 0.13 0.59 ± 0.24 0.22 ± 0.02 0.22 ± 0.05
*
 
    Day 20 of gestation 0.57 ± 0.03 0.35 ± 0.04 0.23 ± 0.07 0.80 ± 0.25 
    Day of delivery 0.27 ± 0.04 0.25 ± 0.01 0.25 ± 0.04 0.62 ± 0.10
*†‡
 
Docosapentaenoic acid (22:5 n-3)    
    Before pregnancy 0.42 ± 0.07 0.79 ± 0.32 0.49 ± 0.09 0.56 ± 0.15 
    Day 7 of gestation 0.90 ± 0.04 0.71 ± 0.05 0.49 ± 0.02 0.55 ± 0.04 
    Day 14 of gestation 1.16 ± 0.25 0.83 ± 0.03 0.41 ± 0.11
*
 0.49 ± 0.10
*
 
    Day 20 of gestation 1.15 ± 0.15 0.92 ± 0.18 0.40 ± 0.05 0.82 ± 0.18 
    Day of delivery 1.20 ± 0.09 1.12 ± 0.07 0.98 ± 0.08 0.82 ± 0.02
*
 
Data are means ± SEM (n = 5). Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.
 
 
*
p < 0.05 vs. Control, 
†
p < 0.05 vs. 20F,
 ‡
p < 0.05 vs. 30F, 
§
p < 0.05 vs. 40F; -, insufficient 
sample volumes. All groups were compared with One-way ANOVA. 
 
n-6 PUFA 
On day 7 of gestation, linoleic acid (18:2 n-6) was increased in 30F mothers compared to the 
other groups (Table 4.6). On day 14 of gestation, the 30F mothers had a reduced dihomo-γ 
linolenic acid (20:3 n-6) compared to control mothers; on day 20 of gestation, dihomo-γ linolenic 
acid (20:3 n-6) was reduced in 30F mothers compared to the other groups (Table 4.6). On the 
day of delivery, docosapentaenoic acid (20:5 n-6) was reduced in 40F mothers compared to 
control and 20F mothers (Table 4.6). 
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Table 4.6 Maternal serum n-6 polyunsaturated fatty acids compositions (%) 
 Control 20F 30F 40F 
Linoleic acid (18:2 n-6)     
    Before pregnancy 16.15 ± 1.93 19.97 ± 1.02 13.67 ± 1.80 14.72 ± 1.36 
    Day 7 of gestation 16.71 ± 0.47 18.63 ± 0.41 22.47 ± 0.97
*†§
 17.58 ± 0.76 
    Day 14 of gestation 15.39 ± 0.53 18.18 ± 0.11 14.86 ± 3.04 16.32 ± 1.77 
    Day 20 of gestation 18.49 ± 2.46 17.91 ± 0.57 19.44 ± 1.05 16.87 ± 0.28 
    Day of delivery 20.65 ± 1.23 16.02 ± 1.26 21.22 ± 0.91 16.95 ± 1.84 
Dihomo-γ linolenic acid  
(20:3 n-6) 
    
    Before pregnancy 0.50 ± 0.04 0.48 ± 0.05 0.46 ± 0.07 0.48 ± 0.11 
    Day 7 of gestation 1.06 ± 0.10 0.86 ± 0.12 0.77 ± 0.06 1.00 ± 0.14 
    Day 14 of gestation 0.92 ± 0.08 0.76 ± 0.09 0.49 ± 0.07
*
 0.65 ± 0.07 
    Day 20 of gestation 0.84 ± 0.05 0.68 ± 0.06 0.37 ± 0.07
*†§
 0.77 ± 0.04 
    Day of delivery 0.94 ± 0.05 0.54 ± 0.03 0.79 ± 0.12 0.78 ± 0.18 
Docosapentaenoic acid  
(22:5 n-6) 
    
    Before pregnancy - 0.10 ± 0.00 - 0.90 ± 0.57 
    Day 7 of gestation 0.22 ± 0.03 0.58 ± 0.35 0.08 ± 0.04 0.36 ± 0.03 
    Day 14 of gestation 0.25 ± 0.05 0.27 ± 0.05 0.34 ± 0.23  0.66 ± 0.19 
    Day 20 of gestation 0.46 ± 0.02 0.90 ± 0.27 1.66 ± 1.19 2.78 ± 0.04 
    Day of delivery 0.66 ± 0.06 1.11 ± 0.15 1.60 ± 0.16 2.59 ± 0.48
*†
 
Data are means ± SEM (n = 5). Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.
 
*
p < 0.05 vs. Control, 
†
p < 0.05 vs. 20F,
 
-, insufficient sample volumes. All groups were 
compared with One-way ANOVA. 
4.1.1.5 Maternal serum fatty acids ratios on the day of delivery  
The 30F mothers had increased total PUFA/total SFA ratios compared to control mothers (Table 
4.7). The ratio of total MUFA/total SFA was elevated in 40F mothers compared to 20F and 30F 
mothers (Table 4.7). 
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Table 4.7 Maternal serum fatty acids ratios  
Ratio Control 20F 30F 40F 
16:1 n-7/16:0 0.05 ± 0.01 0.03 ± 0.01 0.03 ± 0.005 0.043 ± 0.01 
Total PUFA/Total SFA 1.03 ± 0.06 1.23 ± 0.03 1.28 ± 0.03* 1.23 ± 0.07 
Total MUFA/Total SFA 0.28 ± 0.01 0.26 ± 0.01 0.27 ± 0.03 0.38 ± 0.04†‡ 
Total PUFA/Total MUFA 3.79 ± 0.25 4.75 ± 0.26 4.83 ± 0.50 3.20 ± 0.21 
Total n-6 PUFA/Total n-3 
PUFA  6.28 ± 0.42 5.97 ± 0.24 7.85 ± 0.51 7.17 ± 0.83 
Data are means ± SEM (n = 5). Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet. 
*
p < 0.05 vs. Control, 
†
p < 0.05 vs. 20F,
 ‡
p < 0.05 vs. 30F. All groups were compared with One-
way ANOVA. 
4.1.2.1 Neonatal hepatic and skeletal muscle IR, IRS2 and PI3K mRNA expression 
Foetal programming, with maternal diets varying in fat content, did not affect neonatal hepatic 
IR (Fig. 4.1A) and IRS2 (Fig. 4.1B) mRNA expression. However, hepatic PI3K mRNA 
expression was elevated in 30F neonates compared to 20F neonates (Fig. 4.1C). Gel 
electrophoresis for total RNA is shown in Appendix C (Fig C.1A).  
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Figure 4.1 Neonatal hepatic IR, IRS2 and PI3K mRNA expression. (A), Neonatal hepatic 
IR mRNA expression; (B), Neonatal hepatic IRS2 mRNA expression; (C), Neonatal hepatic 
PI3K mRNA expression. Data are means ± SEM. n = 3-10 for hepatic mRNA expression. 
Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.
 †
p<0.05 vs. 20F. 
 
 
Skeletal muscle IR mRNA was reduced in the 30F and 40F neonates compared to 20F neonates 
(Fig. 4.2A). There were no significant differences in neonatal skeletal muscle IRS2 mRNA 
expression among the groups (Fig. 4.2B). However, neonatal skeletal muscle PI3K mRNA 
expression was reduced in 30F and 40F neonates compared to 20F neonates (Fig. 4.2C). Gel 
electrophoresis for total RNA is shown in Appendix C (Fig C.1B).  
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Figure 4.2 Skeletal muscle IR, IRS2 and PI3K mRNA expression. (A), Neonatal skeletal 
muscle IR mRNA expression; (B), Neonatal skeletal muscle IRS2 mRNA expression; (C), 
Neonatal skeletal muscle PI3K mRNA expression. Data are means ± SEM. n = 10 for 
skeletal muscle mRNA expression. Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% 
fat diet.
 †
p<0.05 vs. 20F. 
4.1.2.2 Neonatal hepatic and skeletal muscle IRα, IRS2 and PI3K-p110α immunoreactivity  
Hepatic IRα immunoreactivity was reduced in 40F neonates compared to control and 20F 
neonates (Fig. 4.3B). Further, skeletal muscle IRα immunoreactivity was reduced in 30F and 40F 
neonates compared to control neonates (Fig. 4.4B). There were however no significant 
differences in hepatic (4.5B) and skeletal muscle IRS2 (Fig. 4.6B) and p110α immunoreactivity 
(Fig. 4.7A and B). Neonatal liver and skeletal muscle H and E staining are shown in Appendix A 
(Fig A.1). IRβ and IRS1 were also immunostained but not analysed as it was outside of the scope 
of this study. The representative immunoreactivity images for IRβ (Fig. B.1) and IRS1 (Fig. B.2) 
are shown in Appendix B.  
 
A B 
C 
† † 
Control 20F 30F 40F
0.0
0.5
1.0
1.5
S
k
e
le
ta
l 
m
u
sc
le
 I
R
 m
R
N
A
 e
x
p
re
ss
io
n
Control 20F 30F 40F
0
1
2
3
S
k
e
le
ta
l 
m
u
sc
le
IR
S
2
 m
R
N
A
 e
x
p
re
ss
io
n
Control 20F 30F 40F
0.0
0.2
0.4
0.6
0.8
1.0
S
k
e
le
ta
l 
m
u
sc
le
 P
I3
K
 m
R
N
A
 e
x
p
re
ss
io
n
† † 
 
 
 
 
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Neonatal hepatic IRα immunoreactivity. (A), Neonatal liver immunostained with anti-IRα in Control (Ai), 20F (Aii), 30F 
(Aiii) and 40F (Aiv); (B), Neonatal hepatic IRα immunoreactivity. Data are means ± SEM. n = 6 for immunoreactivity. Control; 20F, 20% 
fat diet; 30F, 30% fat diet; 40F, 40% fat diet.
 *
p<0.05 vs. control; 
†
p<0.05 vs. 20F. 
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Figure 4.4 Neonatal skeletal muscle IRα immunoreactivity. (A), Neonatal skeletal muscle immunostained with anti-IRα in Control (Ai), 
20F (Aii), 30F (Aiii) and 40F (Aiv); (B), Neonatal hepatic IRα immunoreactivity. Data are means ± SEM. n = 6 for immunoreactivity. 
Control; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.
 *
p<0.05 vs. control. 
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Figure 4.5 Neonatal hepatic IRS2 immunoreactivity. (A), Neonatal liver immunostained with anti-IRS2 in Control (Ai), 20F (Aii), 30F 
(Aiii) and 40F (Aiv); (B), Neonatal hepatic IRS2 immunoreactivity. Data are means ± SEM. n = 6 per group. Control; 20F, 20% fat diet; 
30F, 30% fat diet; 40F, 40% fat diet.
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Figure 4.6 Neonatal skeletal muscle IRS2 immunoreactivity. (A), Neonatal skeletal muscle immunostained with ant-IRS2 in Control (Ai), 
20F (Aii), 30F (Aiii) and 40F (Aiv); (B), Neonatal hepatic IRS2 immunoreactivity. Data are means ± SEM. n = 6 per group. Control; 20F, 
20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet. 
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Figure 4.7 Neonatal hepatic and skeletal muscle PI3K-p110α immunoreactivity. (A), 
Neonatal hepatic PI3K-p110α immunoreactivity; (B), Neonatal skeletal muscle PI3K-p110α 
immunoreactivity. Data are means ± SEM. n = 6 per group. Control; 20F, 20% fat diet; 30F, 30% 
fat diet; 40F, 40% fat diet. 
A 
B 
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4.2 PILOT STUDY  
4.2.1. Maternal food intake and body weight and litter size  
There were no differences in maternal calorie intake and body weights throughout gestation and 
on the day of delivery or in litter size amongst the groups (Table 4.8). Further, there were no 
differences in maternal liver, heart, brain and pancreas weights amongst the groups (Table 4.8). 
 
Table 4.8 Maternal food intake and body weight during gestation, organ weights and litter 
size 
Parameter Control Control-Al HFD HFD-Al 
Calorie intake 
(Kcal/g) 
        
Week 1 (e0-e7) 1691 ± 57.33 1671 ± 63.54  1723 ± 90.58 1900 ± 137.3 
Week 2 (e8-e14 1570 ± 42.58 1688 ± 35.79 1715 ± 44.25 1611 ± 63.81 
Week 3 (e15-e21) 1510 ± 52.05 1467 ± 50.98 1538 ± 58.09 1640 ± 85.32 
Overall (Kcal/g) 4771 ± 151.96 4826 ± 150.31 4976 ± 192.92 5151 ± 286.43 
Body weight (g)         
Week 1 (e7) 261 ± 6.35 2720 ± 6.99 282 ± 2.34 285 ± 12.71 
Week 2 (e0) 295 ± 7.35 303 ± 6.72 315 ± 6.72 318 ± 12.53 
Week 3 (e20) 356 ± 12.86 369 ± 5.69 382 ± 20.84 395 ± 16.20 
Day of delivery  267 ± 12.74 300 ± 18.42 304 ± 6.43 302 ± 14.11 
Organ weights (g)     
   Liver 10.01 ± 0.38 10.65 ± 0.45 11.18 ± 0.47 11.32 ± 0.47 
   Heart 0.89 ± 0.08 0.91 ± 0.06 0.97 ± 0.02 1.12 ± 0.07 
   Brain 1.75 ± 0.05 1.82 ± 0.08 1.87 ± 0.02 1.79 ± 0.03 
   Pancreas 1.03 ± 0.10 1.34 ± 0.20 1.47 ± 0.12 1.25 ± 0.13 
Litter size 12.0 ± 0.95 11.2 ± 1.39 12.0 ± 2.04 12.8 ± 1.56 
Data are means ± SEM; n = 5 per group. Control; Control-Al, control-Aspalathus linearis; HFD, 
high fat diet; HFD-Al, HFD-Aspalathus linearis. All groups were compared with One-way 
ANOVA. 
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4.2.2. Maternal blood glucose, serum insulin and glucagon concentrations and homeostasis 
model assessment for insulin resistance (HOMA-IR) 
The HFD-Al mothers presented elevated blood glucose concentrations on day 20 of gestation 
compared to control mothers (Fig. 4.8A). There were no other differences in blood glucose 
concentrations throughout gestation (Fig. 4.8A) and on the day of delivery (Fig.4.8B). Further, 
on the day of delivery, there were no differences in serum insulin (Fig. 4.8C) and serum 
glucagon (Fig. 4.8D) concentrations and HOMA-IR (Fig. 4.8E).  
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Figure 4.8 Maternal blood glucose, serum insulin and serum glucagon concentrations, 
and HOMA-IR. (A), Maternal blood glucose concentrations during pregnancy; (B), Maternal 
blood glucose concentrations on the day of delivery; (C), Maternal serum insulin 
concentrations on the day of delivery; (D), Maternal serum glucagon concentrations on the day 
of delivery; (E), Maternal HOMA-IR on the day of delivery. Data are means ± SEM; n = 5 per 
group. Control; Control-Al, control-Aspalathus linearis; HFD, high fat diet; HFD-Al, HFD-
Aspalathus linearis. *p<0.05 vs. control. 
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4.2.3 Neonatal anthropometric measurements  
For each group of neonates, head length, width, circumference, crown-rump and crown-tail 
lengths were measured in millimetres (mm) (Table 4.9). The HFD-Al neonates had increased 
head length and width compared to control neonates. The head circumference of HFD-Al 
neonates were increased compared to control and control-Al neonates also increased in HFD 
neonates compared to control neonates (Table 4.9). The crown-rump length and crown-tail 
length of Control-Al neonates were increased compared to control and HFD-Al neonates; the 
crown-tail length of the HFD-Al neonates was reduced compared to HFD neonates (Table 4.9).  
 
Table 4.9 Neonatal anthropometry (head length, width, circumference, crown-rump and 
crown-tail length)  
 Control Control-Al HFD HFD-Al 
Head length (mm) 15.4 ± 0.12 15.69 ± 0.15 15.7 ± 0.14 16.24 ± 0.22
*
 
Head width (mm) 12.47 ± 0.32  12.52 ± 0.17 12.74 ± 0.19 13.46 ± 0.32
*
 
Head circumference 
(mm) 
32.53 ± 0.32 33.04 ± 0.25 34.33 ± 0.29
*
 35.19 ± 0.49
*†
 
Crown-rump (mm) 41.33 ± 0.42 43.66 ± 0.69
*§
 41.93 ± 0.46 40.83 ± 0.23 
Crown-tail (mm) 58.59 ± 0.97  62.77 ± 0.88
*§
 61.5 ± 1.01 56.35 ± 0.70
‡
 
Data are means ± SEM; n = 24-31. Control; HFD, Control-Al, control-Aspalathus linearis; high 
fat diet; HFD-Al, HFD-Aspalathus linearis. 
*
p < 0.05 vs. Control, 
†
p < 0.05 vs. Control-Al, 
‡
p < 
0.05 vs. HFD, 
§
p < 0.05 vs. HFD-Al. All groups were compared with One-way ANOVA. 
4.2.4 Neonatal gender distribution, body weight and organ weights 
There was no difference in the distribution of male and female neonates between the groups 
(Table 4.10). Control-Al, HFD and HFD-Al neonates were all heavier than control neonates 
(Table 4.10). Brain weight was increased in the HFD neonates compared to control and Control-
Al neonates (Table 4.10). There were no significant differences in liver and pancreas weights 
amongst the groups. 
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Table 4.10 Neonatal gender distribution, body weight, and liver, brain and pancreas 
weights 
  Control Control-Al HFD HFD-Al 
Male (%) 59.46 ± 4.94 54.8 ± 7.64 40.63 ± 4.86 50.34 ± 2.16 
Female (%) 40.58 ± 4.95 45.2 ± 7.64 59.18 ± 4.88 49.66 ± 2.16 
Body weights 
(g) 
6.052 ± 0.10 6.595 ± 0.11
*
 6.831 ± 0.12
*
 6.665 ± 0.11
*
 
Liver (g) 0.223 ± 0.01 0.237 ± 0.01 0.243 ± 0.004 0.238 ± 0.01 
Brain (g) 0.244 ± 0.01 0.241 ± 0.01 0.274 ± 0.004
*†
 0.252 ± 0.01 
Pancreas (g) 0.025 ± 0.003 0.02 ± 0.001 0.024 ± 0.003 0.026 ± 0.01 
Heart (g) 0.89 ± 0.08 0.91 ± 0.06 0.97 ± 0.02 1.12 ± 0.07 
Data are means ± SEM; n = 24-31). Control; Control-Al, control-Aspalathus linearis; HFD, high 
fat diet; HFD-Al, HFD-Aspalathus linearis. 
*
p < 0.05 vs. Control, 
†
p < 0.05 vs. Control-Al. All 
groups were compared with One-way ANOVA. 
 
4.2.5 Neonatal blood glucose and serum insulin concentrations and HOMA-IR 
HFD and HFD-Al neonates had reduced glucose concentrations compared to control and 
Control-Al neonates (Fig. 4.9A). There were no significant differences in serum insulin 
concentrations (Fig. 4.9B) or HOMA-IR (Fig. 4.9C) amongst the groups. There were insufficient 
sera volumes for the determination of glucagon concentrations. 
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Figure 4.9 Neonatal blood glucose and serum insulin concentrations and HOMA-IR. (A), 
Neonatal blood glucose concentrations; (B), Neonatal serum insulin concentrations; (C), 
HOMA-IR in neonates. Data are means ± SEM. Control; Control-Al, control-Aspalathus 
linearis; HFD, high fat diet; HFD-Al, HFD-Aspalathus linearis.
 *
p<0.05 vs. control; 
†
p<0.05 
vs. Control-Al.  
A B 
C 
*† *† 
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CHAPTER 5 
DISCUSSION 
 
5.1 Introduction to the main study 
In our previous studies, the 20F neonates had elevated blood glucose concentrations compared to 
control neonates but this did not reflect hyperglycaemia as it was within the physiological range 
(Cerf et al., 2011). The serum insulin and glucagon concentrations remained unaltered (Cerf et 
al., 2011). We further investigated neonatal brain glucose transporter 2 (GLUT2) and 
neuropeptide Y expression. Both the 30F and 40F neonates displayed increased brain GLUT2 
and neuropeptide Y immunoreactivity (Cerf et al., 2010) which may represent early events in the 
development of obesity and T2D. Hepatic GLUT2 and glucokinase (GCK) mRNA expression 
and immunoreactivity showed no significant differences amongst the groups (Cerf et al., 2011). 
This prompted further studies on foetal programming of metabolic disease. The present study 
therefore aimed to investigate the effect of gestational maternal diets varying fat (as energy) on 
proximal hepatic and skeletal muscle insulin signalling in neonatal Wistar rat offspring 
specifically focusing on IRα, IRS2 and PI3K-p110α.  
5.1.1. Skeletal muscle  
Skeletal muscle is the major site for insulin stimulated glucose uptake (Lin and Sun, 2010). The 
development of insulin resistance in skeletal muscle is critical in the pathogenesis of T2D (Yan 
et al., 2011). Foetal life is important for skeletal muscle development; after birth there is no net 
increase in the number of muscle fibers (Nissen et al., 2003). Late foetal life is also important for 
adipogenesis which may increase intracellular adipogenesis in skeletal muscle leading to insulin 
resistance (Du et al., 2010). Abnormal skeletal muscle development has been reported in several 
studies; offspring from mothers fed a cafeteria during gestation and lactation had reduced 
myocyte proliferation and insulin receptor mRNA expression (Bayol et al., 2005). In this study, 
neonates from mothers fed a 30% fat (30F) or 40% fat (40F) fat diet during gestation had a 
reduced IR and PI3K mRNA expression compared to neonates from mothers fed a 20% fat (20F) 
diet. These findings suggest compromised proximal insulin signalling, at the gene level, in 30F 
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and 40F neonates relative to 20F neonates. In skeletal muscle, reduced PI3K-p110β mRNA 
expression was reported in female offspring from obese mice (Shelley et al., 2009).  
In the present study, the 30F and 40F neonates had a reduced IRα immunoreactivity compared to 
control neonates with no significant changes in both IRS2 and PI3K-p110α immunoreactivity. 
The reduced IRα immunoreactivity may reflect impaired skeletal muscle proximal insulin 
signalling in 30F and 40F neonates. A decline in IR autophosphorylation of IRS1 and PI3K-p110 
phosphorylation suggests impairment in early events of the insulin signalling pathway in high fat 
fed animals (Hansen et al., 1998). 
The present study did not investigate IRS1 mRNA and protein expression but instead focused on 
IRS2. IRS2 was initially identified as an alternative in animals with IRS1 defects (Sesti et al., 
2001). Both IRS1 and IRS2 may regulate unique signalling pathways in different tissues but both 
mediate metabolic pathways (Sesti et al., 2001). Based on the results obtained, further 
investigation on the phosphorylation of these insulin signalling cascades is warranted. In 
addition, the programming effects of maternal fat diets on offspring physiology and metabolism 
should be gender specific. 
5.1.2. Liver 
Offspring from mothers fed a “junk” diet had reduced hepatic IR and IGF mRNA expression 
with reduced hepatic IRS2 and GLUT2 mRNA expression compared to control offspring (Bayol 
et al., 2010), which was indicative of hepatic insulin resistance. We previously found no 
significant changes in both hepatic GLUT2 and GK mRNA expression and immunoreactivity 
(Cerf et al., 2011). In the present study, no changes in hepatic IR and IRS2 mRNA expression 
were found. However, hepatic IRα immunoreactivity was reduced in 40F neonates compared to 
control and 20F neonates which may reflect impaired hepatic insulin signalling at the receptor 
level. Therefore proximal insulin signalling may be compromised thereby limiting the effect of 
insulin’s action in the liver. Specifically, reduced hepatic IRα immunoreactivity induced by high 
fat foetal programming may result in the inability of insulin to suppress hepatic gluconeogenesis 
thereby stimulating glycogen synthesis leading to hyperglycaemia and insulin resistance. 
However, there were no changes in glycaemia in 40F neonates (Cerf et al., 2011). β cell 
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compensation may prevent hyperglycaemia at the neonatal life stage but these neonates may be 
glucose intolerant. Further, with age, the adverse effects of foetal programming may become 
more profound particularly with additional insults such as prolonged high fat diet consumption. 
In rodents, offspring from high fat fed mothers showed reduced protein expression of hepatic 
IRβ and IRS1 but elevated protein expression of PKC-ζ, independent of hyperglycaemia 
(Buckley et al., 2005; Considine et al., 1995). Based on the results, further investigation on the 
phosphorylation of insulin signalling cascades, including PKC, PKB, DAG and ceramide is 
required to link the proximal and distal factors of insulin signalling.  
The RNA integrity number for all the liver samples was less than 6 (the quality standard) 
therefore the RNA integrity of the samples was degraded. New samples should be analysed by 
qPCR to validate the hepatic gene expression findings. Further, there was disparity between the 
mRNA and protein expression (immunoreactivity) in liver samples which may be due to 
stability, degradation or contamination of mRNA samples. The IR mRNA and IRα protein 
expression (immunoreactivity) were reduced in 30F and 40F neonates compared to 20F neonates 
reflecting some changes in gene expression. The IRS2 mRNA and protein expression were not 
altered in both liver and skeletal muscle.  
5.2. Maternal serum lipid profiles  
The current evidence shows that FFA are implicated in obesity, insulin resistance and type 2 
diabetes (Eckel et al., 2005). Endogenous fatty acids are the best biomarkers for FFA intake 
since they cannot be synthesised from carbohydrates (Riserus et al.,2009). The various FFA 
consumed by mothers during gestation play crucial roles in the growth and development of their 
foetuses. Maternal circulating FFA are correlated to the foetal circulating FFA with reduced total 
concentrations in foetuses relative to mothers (Cetin et al., 2002). Changes in maternal and foetal 
plasma FFA concentrations may lead to the development of metabolic disease including type 2 
diabetes. Animal studies demonstrated that insulin sensitivity is impaired by SFA and improved 
by PUFA (omega 3) (Siri-Tarino et al., 2010). In rats, SFA have shown to increase intramuscular 
palmitic acid (16:0) accumulation that may lead to insulin resistance in (Reynoso et al., 2003).  
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The present study investigated the changes in serum lipids of pregnant mothers fed diets varying 
in fat (as energy) throughout the gestation period. Previous studies have demonstrated that high 
fat diet fed rats exhibited a significant increase in total triglyceride and cholesterol 
concentrations compared to control rats (Srinivasan et al., 2008). In contrast, in our study, there 
were no significant changes in serum total triglyceride, cholesterol and FFA concentrations. 
Therefore we further investigated serum total and individual FFA composition.  
Previous studies in humans reported a positive association between serum FFA composition and 
diabetes, characterised by higher proportions of palmitic acid (16:0), dihomo-γ-linolenic (20:3 n-
6) and palmitoleic acid (16:1 n-7) in cholesterol esters with low proportions of linoleic acid (18:2 
n-6) (Coelho et al., 2011; Vessby et al., 1994). In this study, we found a reduction in total SFA 
composition in 30F and 40F mothers compared to control mothers. Further, circulating palmitic 
acid (16:0) and stearic acid (18:0) were not affected by diet varying in fat (as energy) in these 
mothers. We further investigated the palmitoleic (16:1 n-7)/palmitic (16:0) ratio which is a better 
marker for palmitic acid (16:0) intake via activity of desaturate enzyme (Warensjo et al., 2008). 
The serum palmitoleic (16:1 n-7)/palmitic (16:0) ratio was unaltered. However, circulating 
palmitoleic acid was reduced in both 30F and 40F mothers on day 14 of gestation. Therefore, a 
reduction in SFA and circulating palmitoleic acid may reflect transient improved insulin 
sensitivity in both 30F and 40F mothers at this specific time points in gestation.  
MUFA have been reported to improve insulin sensitivity and SFA reduced insulin sensitivity by 
24% compared to MUFA in overweight subjects (Riserus et al., 2009). The total MUFA and 
oleic acid (18:1 n-9) composition was increased in 40F mothers compared to both 20F and 30F 
mothers on the day of delivery with no detected changes in 40F mothers compared to control 
mothers. This may reflect improved insulin sensitivity at delivery in 40F mothers relative to 20F 
and 30F mothers.  
PUFA, particularity the omega-3 fatty acids docosahexaeonic acid (22:6 n-3) and 
eicosapentaenoic acid (20:5 n-3), have been reported to improve insulin sensitivity compared to 
SFA (Riserus et al., 2009). In high fat diet fed rats, dietary intake of medium and long-chain 
triglycerols ameliorated insulin resistance (Terada et al., 2012). This may be due to their greater 
oxidative rates compared to SFA (Coelho et al., 2011). Other studies have shown that FFA 
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oxidation increases proportionately with PUFA/SFA ratio (Bradshaw et al., 2009; Coelho et al., 
2011). In this study, the total n-3 PUFA was reduced in both 30F and 40F mothers on day 7 of 
gestation which may reflect insulin insensitivity in early gestation. On the day of delivery, the 
total n-3 PUFA remained reduced (albeit not significant) in 30F and 40F mothers. Linoleic acid 
(18:3 n-3) was also reduced in both 30F and 40F mothers on day 7 of gestation. On day 14 of 
gestation, docosapentaenoic acid (22:5 n-3) was reduced in 30F and 40F mothers. This reduction 
in total and specific n-3 PUFA may reduce insulin sensitivity of the mothers and developing 
foetus. However, the n-6 PUFA/n-3 PUFA ratio was not affected.  
5.3. Pilot study: Aspalatus linearis (green rooibos) 
The prevalence of T2D in children continues to increase globally. Maternal over-nutrition is 
associated with an increased risk of metabolic disease including T2D later in life. Rooibos tea is 
considered healthy and safe to drink during pregnancy due to the absence of alkaloids and low 
tannin content (Joubert et al., 2008). Rooibos tea contains several active compounds; one of the 
major active compounds is aspalatin, a flavanoid that is unique to rooibos and believed to be 
partially responsible for its hypoglycaemic effects (Son et al., 2012; Kawano et al., 2009). 
Aspalatin has been reported to improve glucose tolerance in vivo (Kawano et al., 2009). In this 
study, we assessed the therapeutic potential of Aspalatus linearis extract (aspalatin-enriched) on 
the programming effects of a high fat diet. The HFD-Al mothers had elevated blood glucose 
concentrations on day 20 of gestation; however this did not reflect hyperglycaemia as it was 
within the physiological range. The rooibos tea extract had no effect on maternal serum insulin 
and glucagon concentration. In addition, there were no differences in insulin sensitivity as 
estimated by HOMA-IR. Further, there were no changes in maternal calorie intake, body weights 
and organ weights (liver, heart, brain and pancreas). We also found no differences in litter size 
among the groups. These findings suggested that rooibos tea extract had neither harmful nor 
ameliorative effects in pregnant mothers.  
In the present study, HFD neonates had increased head circumference, brain weight and body 
weight compared to control neonates reflecting more rapid growth and development. Increased 
body weight in HFD neonates may reflect adiposity which should be investigated further. 
Offspring from rats fed a high fat diet (35% fat) during gestation displayed elevated FFA 
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concentrations which could lead to increased adiposity and insulin resistance late in life 
(McCurdy et al., 2009). The HFD-Al neonates were heavier than control neonates with no 
differences between HFD and HFD-Al neonates. Therefore Aspalathus linearis supplementation 
in offspring maintained on a high fat diet increased body weight and did not reduce body weight 
in high fat exposed neonatal progeny.  
The hypoglycaemic effect of aspalatin has been reported to be via AMPK activation to promote 
endogenous GLUT4 translocation in L6 myocytes (Son et al., 2012). However, the HFD and 
HFD-Al neonates displayed reduced blood glucose concentrations compared to control neonates. 
With the insult of high fat diet consumption, Aspalathus linearis treatment may therefore hold 
some glucose lowering potential. This should be confirmed in further studies. Serum insulin 
concentrations and HOMA-IR were not affected but these could potentially be altered as 
glycaemia fluctuates.  
ROS triggers insulin resistance (Kawano et al., 2009). By reducing oxidative stress, Aspalathus 
linearis may prevent peripheral and tissue-specific insulin resistance. In STZ-induced diabetic 
rats, rooibos tea partially ameliorated oxidative stress (Ulicna et al., 2006). Therefore oxidative 
stress should be assessed in foetal programmed progeny and their mothers.  
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CHAPTER 6 
CONCLUSION AND FUTURE WORK 
 
6.1 Study limitations 
A limitation of the present study was low sera volumes for maternal lipidaemia analyses as only 
total cholesterol concentrations were determined without measuring HDL and LDL cholesterol.  
The study could be strengthened by determining insulin signalling phosphorylation which 
reflects activity of these insulin signalling cascades and could reinforce some of the findings. 
Further, Western blot analyses could confirm our immunoreactivity findings.  
Gender specific programming effects also present a limitation as the physiological systems and 
hormones differ in males and females. 
6.2 Conclusion and future work  
The overall aims of the study was to investigate the effects of maternal diets varying in fat 
content on neonatal gene and protein expression profiles of proximal insulin signalling factors 
(IRα, IRS2 and PI3K-p110α) and to assess the therapeutic potential of Aspalathus linearis (green 
rooibos) on the programming effects of a high fat diet.  
Foetal high fat programming reduced neonatal IRα immunoreactivity in both the liver and 
skeletal muscle which may impair proximal insulin signalling in these organs at the receptor 
level. Further, skeletal muscle IR and PI3K mRNA expression were also reduced by high fat diet 
in the 30F and 40F neonates compared to 20F neonates. However, hepatic IR and IRS2 mRNA 
expression was not affected and further studies are needed. High fat diet had no effect of 
maternal circulating total FFA, triglycerides and cholesterol concentrations. The reduction in 
total and specific omega 3 fatty acids may have a negative impact on the insulin sensitivity of the 
mother and foetus.  
Aspalathus linearis had no effect of maternal serum insulin and glucagon concentrations. In 
addition, maternal calorie intake, body weight and organ weights (liver, brain and pancreas) were 
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not altered amongst the groups, suggesting that rooibos had neither harmful nor ameliorative 
effects pregnant mothers. The HFD-Al neonates were heavier than control neonates suggesting 
that rooibos treatment at the dose of 150 mg/kg had no ameliorative effect on the body weight of 
offspring from mothers fed high fat diet during pregnancy.  
Futures studies  
New samples should be analysed for qPCR to validate the gene expression findings of the 
present study. Based on the results obtained, further investigation on the phosphorylation of 
these insulin signalling cascades is warranted. In addition, the programming effects of maternal 
fat diet on offspring physiology and metabolism should be gender specific.  
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APPENDIX A 
HAEMATOXYLIN AND EOSIN STAINING OF NEONATAL LIVER AND SKELETAL MUSCLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
Figure A.1 Morphological analysis of neonatal tissue using haematoxylin and eosin stain. (A), Neonatal liver, Control (Ai), 20F (Aii), 
30F (Aiii) and 40F (Aiv); (B), Neonatal skeletal muscle, Control (Bi), 20F (Bii), 30F (Biii) and 40F (Biv). Control; 10F, 10% fat diet; 20F, 
20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.  
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APPENDIX B 
 IMMUNOHISTOCHEMICAL STAINING FOR NEONATAL LIVER AND SKELETAL MUSCLE IRβ AND IRS1 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure B.1 Neonatal hepatic and skeletal muscle IRβ immunoreactivity. (A), Neonatal liver immunostained with ant-IRβ in Control (Ai), 
20F (Aii), 30F (Aiii) and 40F (Aiv); (B) Neonatal skeletal muscle immunostained with ant-IRβ in Control (Bi), 20F (Bii), 30F (Biii) and 40F 
(Biv). Control; 10F, 10% fat diet; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet.  
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Figure B.2 Neonatal hepatic and skeletal muscle IRS1 immunoreactivity. (A), Neonatal liver immunostained with ant-IRS1 in Control 
(Ai), 20F (Aii), 30F (Aiii) and 40F (Aiv); (B) Neonatal skeletal muscle immunostained with ant-IRS1 in Control (Bi), 20F (Bii), 30F (Biii) and 
40F (Biv).Control; 10F, 10% fat diet; 20F, 20% fat diet; 30F, 30% fat diet; 40F, 40% fat diet. 
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APPENDIX C 
TOTAL RNA QUALITY CONTROL  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C.1 Total RNA quality control. (A) Liver samples; (B) Skeletal muscle samples 
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APPENDIX D 
 
Table D.1 Antibodies used in immunehistochemical (IHC) staining  
Antibody Clonality Company  
IRα (ab78424) Rabbit polyclonal Abcam, Cambridge, UK 
IRS2 (H-205) : (sc-8299) Rabbit polyclonal Santa Cruz Biotechnology, Santa 
Cruz, CA, USA 
PI3K-p110α (C73F8) Rabbit monoclonal Cell signalling Technology, 
Danvers, MA, USA 
IRβ (C-19) : (sc-711) Rabbit polyclonal  Santa Cruz Biotechnology, Santa 
Cruz, CA, USA 
IRS1 (1M92-7)  Mouse monoclonal  Millipore upstate, Singe Oak Drive, 
Temecula, CA, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
87 
 
Table D.2 Buffer and reagents used in IHC 
 
Reagent  Supplier 
0.05M Tris-Buffered Saline (TBS) pH 7.2  
Tris (hydroxymethyl aminomethan)   Merck 
Sodium chloride  Merck 
  
0.1M Phosphate Buffered Saline (PBS) pH 
7.2 
 
Sodium dihydrogen orthophosphate (NaH2PO4)  Merck 
Disodium dihydrogen orthophosphate 
(Na2HPO4) 
Merck 
Sadium chloride Merck 
Bovine serum albumen Merck 
Sodium azide Merck 
  
0.01M Citrate Buffer   
Citric acid (C6H8O7.H2O) Merck 
Tri-sodium citrate  (C6H5Na3O7.2H2O) Merck 
  
Liquid DAB + Substrate Chromagen System DAKO Corporation (Diagnostech) 
  
Normal Horse Serum (NHS)  
65µl NHS diluted in 1235µl 0.1M PBS pH 7.2  
  
Normal Goat Serum (NGS)  
 65µl NGS diluted in 1235µl 0.1M PBS  
  
Biotinylated anti-Mouse IgG Vector Labolatories 
Biotinylated anti-Rabbit IgG Vector Labolatories 
Vectastain ABC kit Vector Labolatories 
  
 
 
 
 
 
